Suppressor of Cytokine Signaling 5 (SOCS5): A Comprehensive Functional Review

Introduction and Summary

Suppressor of Cytokine Signaling 5 (SOCS5) is a member of the SOCS family of intracellular proteins that function as negative regulators of cytokine and growth factor signaling. The human SOCS5 gene (UniProt: O75159, OMIM: 607094) encodes a 536-amino acid protein located on chromosome 2p21 [trengove-2013-socs-review-abstract]. Unlike other SOCS family members that predominantly regulate cytokine receptor signaling, SOCS5 has emerged as a key regulator of receptor tyrosine kinase (RTK) signaling, particularly through its ability to target the epidermal growth factor receptor (EGFR) for degradation [nicholson-2005-socs5-egfr-abstract]. SOCS5 functions through two mechanistically distinct pathways: first, as an E3 ubiquitin ligase adapter that facilitates proteasomal degradation of target receptors, and second, through direct inhibition of Janus kinases (JAK1 and JAK2) via a unique N-terminal region [linossi-2013-socs5-jak-shc1-abstract]. The protein is expressed ubiquitously with notably high expression in the brain and has been implicated in regulating T helper cell differentiation, anti-viral immunity, and cancer suppression.

Domain Architecture and Structural Features

SOCS5 is characterized by three distinct structural domains that are conserved across the SOCS family. The central SH2 (Src Homology 2) domain enables recognition and binding to phosphorylated tyrosine residues on target proteins, while the C-terminal SOCS box (approximately 40 amino acids) functions as an adapter that recruits the E3 ubiquitin ligase machinery [sondergaard-2016-cullin5-review-abstract]. What distinguishes SOCS5 from other SOCS family members is its extended N-terminal region of approximately 369 residues, which it shares only with the closely related SOCS4 [linossi-2013-socs5-jak-shc1-abstract].

The N-terminal region of SOCS5 contains a unique JAK interaction region (JIR), spanning residues 175-244, which enables direct binding to the catalytic domains of JAK kinases with measured binding affinities around 0.5 μM for JAK1 [linossi-2013-socs5-jak-shc1-abstract]. This JIR is conserved between SOCS5 orthologs but is distinct from the kinase inhibitory region (KIR) found in SOCS1 and SOCS3, indicating that SOCS5 employs a fundamentally different mechanism for JAK inhibition. SOCS4 and SOCS5 share 92% amino acid identity within their SH2 domains and approximately 49% overall amino acid identity, suggesting they may have partially overlapping functions [trengove-2013-socs-review-abstract].

The SH2 domain of SOCS5 contains an extended SH2 subdomain (ESS), an N-terminal alpha-helix that stabilizes the phosphotyrosine-binding loop and is characteristic of SOCS family proteins. Surface plasmon resonance studies have determined that the SOCS5 SH2 domain binds to phosphoTyr317 on Shc-1 with high affinity (Kd = 0.16 μM), which represents a 25-fold tighter interaction compared to Shc-1 pY239 and exceeds the affinity for EGFR pY1092 (Kd = 0.87 μM) [linossi-2013-socs5-jak-shc1-abstract]. The SOCS box consists of a BC box and a Cullin5 box that mediate interactions with Elongin B/C and Cullin5, respectively, forming the complete E3 ubiquitin ligase complex [sondergaard-2016-cullin5-review-abstract].

Three-Dimensional Structure

Experimental structural information for SOCS5 is limited to the JAK interaction region within the N-terminal domain. The NMR solution structure of mouse SOCS5 residues 175-244 (PDB ID: 2N34) was determined by Chandrashekaran and colleagues [chandrashekaran-2015-socs5-jir-structure-abstract]. This structure revealed that the JIR, despite being within a largely disordered N-terminal region, contains preformed structural elements consisting of an alpha-helix spanning residues 224-233, preceded by a turn and an extended structure. The presence of these preformed elements within an otherwise disordered region suggests they may serve as recognition motifs for JAK binding, reducing the entropic cost of binding by providing a pre-organized interaction surface.

The structural study also identified a phosphorylation site at Ser211 and investigated its role in modulating JAK interactions [chandrashekaran-2015-socs5-jir-structure-abstract]. Post-translational modification at this site could potentially serve as a regulatory mechanism for SOCS5's interaction with JAK kinases, though the physiological significance of this phosphorylation event remains to be fully characterized.

No crystal or NMR structure is currently available for the full-length SOCS5 protein or for SOCS5 in complex with its binding partners (EGFR, Shc-1, or Elongin B/C-Cullin5). The highly conserved SH2 and SOCS box domains are likely to adopt structures similar to those determined for other SOCS family members, given the high sequence conservation within these regions.

Evolutionary Conservation

SOCS5 is an evolutionarily ancient protein that was present in the common ancestor of animals. The polypeptide sequences of SOCS proteins are highly conserved among mammals; for example, human and porcine SOCS5 share 96.6% amino acid identity. This high degree of conservation suggests strong selective pressure to maintain SOCS5 function throughout vertebrate evolution.

The SOCS gene family in extant vertebrates evolved from ancestral SOCS1/SOCS2/SOCS3/CISH and SOCS4/SOCS5 intermediates through two rounds of whole genome duplications (WGDs). SOCS4 and SOCS5 form a distinct evolutionary clade, sharing significant sequence homology with each other while being more distantly related to other SOCS family members. This evolutionary relationship is consistent with the functional similarities observed between these two proteins, including their roles in regulating receptor tyrosine kinase signaling and their extended N-terminal domains.

In Drosophila melanogaster, the SOCS5 ortholog is Socs36E, which shares 64% identity with human SOCS5 in the conserved carboxy-terminal region (SH2 domain and SOCS box) [stec-2011-drosophila-socs-abstract]. Functional studies in Drosophila have demonstrated remarkable conservation of function across species. Like its mammalian counterpart, Socs36E is both a target gene and negative regulator of JAK/STAT signaling, operating through a classical negative feedback mechanism. Socs36E also weakly inhibits EGFR signaling, mirroring the function of mammalian SOCS5. Importantly, Socs36E has been identified as a tumor suppressor in Drosophila epithelial transformation models, behaving as a cooperating factor that limits EGFR-driven tumorigenesis [stec-2011-drosophila-socs-abstract]. Notably, Socs36E null mutant flies remain viable, similar to SOCS5 knockout mice, suggesting that functional redundancy in signal transduction regulation is a conserved feature across metazoan evolution.

Molecular Function as an E3 Ubiquitin Ligase Adapter

The primary biochemical function of SOCS5 is to serve as a substrate recognition subunit within a Cullin-RING E3 ubiquitin ligase complex. Through its SOCS box domain, SOCS5 recruits Elongin B and Elongin C, which in turn associate with Cullin5 and the RING domain protein Rbx2 [sondergaard-2016-cullin5-review-abstract]. This multi-protein complex enables the transfer of ubiquitin to substrates bound by the SOCS5 SH2 domain, marking them for proteasomal degradation.

The SOCS box is disordered in isolation and only becomes structured upon Elongin B/C association. The interaction depends upon the first 12 residues of the SOCS box domain, particularly a deeply buried, conserved leucine residue. Biochemical studies have determined that SOCS5 binds Cullin5 with high affinity (Kd approximately 10 nM), comparable to other SOCS family members, though this interaction requires prior recruitment of Elongin B/C [sondergaard-2016-cullin5-review-abstract]. The critical recognition motif in the Cullin5 box is defined by the sequence LPΦP (where Φ represents a hydrophobic residue), which mediates specific Cullin5 binding.

This E3 ligase activity is essential for SOCS5's ability to regulate EGFR signaling. When SOCS5 is overexpressed, it promotes enhanced downregulation of EGFR from the cell surface following EGF treatment, primarily through increased receptor degradation rather than altered internalization rates [nicholson-2005-socs5-egfr-abstract]. Importantly, the SOCS box is required for this function, as SOCS box-deleted mutants fail to promote EGFR degradation.

Regulation of Epidermal Growth Factor Receptor Signaling

One of the best-characterized functions of SOCS5 is its role as a negative regulator of EGFR signaling. The initial demonstration of this function came from studies showing that SOCS5 associates with the EGFR complex in an EGF-independent manner and that the mitogenic response to EGF is dramatically inhibited in SOCS5-expressing cell lines compared to control lines [nicholson-2005-socs5-egfr-abstract]. This inhibition occurs through enhanced proteasomal degradation of the EGFR, dependent on SOCS box recruitment of E3 ubiquitin ligase activity.

Both the N-terminal region and the SH2 domain of SOCS5 contribute to EGFR binding. Uniquely, SOCS5 can associate with EGFR independently of receptor phosphorylation, which distinguishes it from many other SH2 domain-containing proteins that require phosphotyrosine recognition for binding [nicholson-2005-socs5-egfr-abstract]. This constitutive association may enable SOCS5 to function as a pre-positioned negative regulator, ready to dampen signaling upon receptor activation.

SOCS5's regulation of EGFR has important physiological consequences. Studies in COPD patients revealed that SOCS5 levels are diminished in respiratory epithelial cells, correlating with increased susceptibility to influenza virus infection [kedzierski-2017-socs5-influenza-abstract]. Using mouse models, researchers demonstrated that SOCS5-deficient animals exhibit heightened disease severity during influenza infection, with increased viral titers and weight loss. This phenotype can be attributed to dysregulated EGFR signaling, as EGFR activation promotes viral replication in epithelial cells. These findings suggest that therapeutic interventions targeting SOCS5 expression could represent a novel treatment strategy for respiratory viral infections.

Beyond EGFR, SOCS5 has also been shown to target other ErbB family members including ERBB2 (HER2) and ERBB4, while sparing other cell surface proteins, indicating substrate specificity within the receptor tyrosine kinase family [nicholson-2005-socs5-egfr-abstract].

Regulation of JAK-STAT Signaling

In addition to its role in RTK signaling, SOCS5 functions as a regulator of the JAK-STAT pathway through a mechanistically distinct mechanism. Studies have demonstrated that SOCS5 can interact directly with JAK kinases via its unique N-terminal JIR, and co-expression of SOCS5 specifically reduces the autophosphorylation of JAK1 and JAK2 while having no effect on JAK3 or TYK2 [linossi-2013-socs5-jak-shc1-abstract]. This selectivity indicates that SOCS5 has evolved to regulate specific subsets of JAK-dependent signaling pathways.

The mechanism of JAK inhibition by SOCS5 appears distinct from that of SOCS1 and SOCS3, which employ a kinase inhibitory region (KIR) to directly block the JAK catalytic site. Mutation of the putative KIR region in SOCS5 (His360) had only a modest impact on JAK1 inhibition compared to deletion of the N-terminus, indicating that SOCS5 uses fundamentally different structural elements for kinase inhibition [linossi-2013-socs5-jak-shc1-abstract]. The JIR alone is unlikely to be a direct JAK inhibitor, suggesting it functions primarily as a binding mediator, with additional N-terminal residues contributing to the inhibitory mechanism.

An important target of SOCS5's JAK regulatory activity is the IL-4 signaling pathway. The initial characterization of SOCS5 function in T helper cell biology demonstrated that SOCS5 protein is preferentially expressed in committed Th1 cells and interacts with the cytoplasmic region of the IL-4 receptor alpha chain [seki-2002-socs5-il4-stat6-abstract]. This interaction is unconventional in that it occurs irrespective of receptor tyrosine phosphorylation, with SOCS5 binding to the box1 region of IL-4R and reducing JAK1 association with the receptor. The functional consequence is inhibition of IL-4-mediated STAT6 activation. Transgenic mice constitutively expressing SOCS5 showed five-fold less Th2 development compared to littermate controls, supporting a role for SOCS5 in promoting Th1-biased immune responses [seki-2002-socs5-il4-stat6-abstract].

Regulation of Growth Factor Adaptor Protein Shc-1

Beyond receptor targeting, SOCS5 has been identified as a potential regulator of downstream signaling adaptor proteins. The identification of phosphoTyr317 on Shc-1 as a high-affinity binding site for the SOCS5 SH2 domain (Kd = 0.16 μM) suggests that SOCS5 may negatively regulate EGF and growth factor-driven Shc-1 signaling [linossi-2013-socs5-jak-shc1-abstract]. Shc-1 is an important adaptor protein that links receptor tyrosine kinases to the Ras-MAPK signaling cascade through recruitment of Grb2. By binding to phosphorylated Shc-1, SOCS5 may compete with Grb2 recruitment and thereby attenuate mitogenic signaling.

This finding positions SOCS5 as a potential regulator of multiple points in growth factor signaling pathways, both at the level of receptor stability (through EGFR degradation) and at the level of downstream signal transduction (through Shc-1 binding). Such multi-layered regulation would be consistent with SOCS5's proposed role as a tumor suppressor.

Subcellular Localization

SOCS5 is primarily a cytoplasmic protein, consistent with its function in regulating cytoplasmic signaling pathways. The Human Protein Atlas indicates ubiquitous cytoplasmic expression across human tissues [trengove-2013-socs-review-abstract]. This localization enables SOCS5 to interact with activated receptor tyrosine kinases at the plasma membrane and with cytoplasmic JAK kinases associated with cytokine receptors.

The predominantly cytoplasmic localization of SOCS5 is consistent with its function as an E3 ligase adapter. By remaining in the cytoplasm, SOCS5 is positioned to encounter activated receptors that have been internalized from the plasma membrane, as well as to associate with receptor complexes at the cell surface. The EGFR, for example, is internalized upon ligand binding and traffics through endosomal compartments where SOCS5-mediated ubiquitination could target it for lysosomal degradation rather than recycling to the plasma membrane.

Tissue Expression and Physiological Roles

Northern blot analysis reveals wide expression of SOCS5 transcripts across human tissues, with a 4.2 kb transcript detected in most tissues tested, though expression is notably weaker in pancreas and spleen [trengove-2013-socs-review-abstract]. SOCS5 was initially identified through screening for cDNAs encoding proteins expressed in brain, and the protein shows notably high expression in multiple brain regions including the cortex, hippocampus, cerebellum, and substantia nigra.

Despite high expression in the brain, SOCS5-deficient mice show no obvious neurological phenotype under normal conditions [brender-2004-socs5-lymphocyte-abstract]. However, when challenged with neurotropic viral infection, the importance of SOCS5 in the central nervous system becomes apparent. Studies using Semliki Forest virus infection in SOCS5-deficient mice revealed that lack of SOCS5 results in more severe neuroinflammation, with increased infiltration of CD11b+ cells, neutrophils, and inflammatory monocytes into the brain [kedzierski-2022-socs5-alphavirus-abstract]. SOCS5-deficient animals also displayed marked vacuolation of grey and white matter with multifocal parenchymal necrosis. These findings indicate that SOCS5 is a vital regulator of anti-viral immunity that mediates the critical balance between immunopathology and virus persistence in the CNS.

The generation of SOCS5 knockout mice by Brender and colleagues revealed that SOCS5-deficient animals are viable, fertile, and show no overt pathological changes [brender-2004-socs5-lymphocyte-abstract]. B and T cell development proceeds normally, and cytokine and antigen-induced proliferative responses remain intact. Notably, the predicted role of SOCS5 in Th1/Th2 differentiation based on overexpression studies was not confirmed in knockout animals, with CD4+ T cells showing normal Th1/Th2 responses both in vitro and in vivo. This discrepancy may be explained by functional redundancy with SOCS4, which shares significant sequence homology with SOCS5. Studies of SOCS4/SOCS5 double knockout mice would be required to fully address this question.

Role in Cancer and Tumor Suppression

Growing evidence supports a role for SOCS5 as a tumor suppressor, primarily through its negative regulation of EGFR and JAK-STAT signaling pathways. Epigenetic silencing of SOCS5 through DNA hypermethylation has been reported in multiple cancer types, including hepatocellular carcinoma, cervical cancer, and thyroid tumors [sharma-2019-socs5-tall-abstract].

In T-cell acute lymphoblastic leukemia (T-ALL), SOCS5 expression is epigenetically regulated by DNA methyltransferase-3A-mediated DNA methylation and methyl CpG binding protein-2-mediated histone deacetylation [sharma-2019-socs5-tall-abstract]. Forced SOCS5 expression in leukemic cells inhibits proliferation and cell cycle progression, while SOCS5 inactivation accelerates leukemia engraftment in mouse models. Interestingly, SOCS5 silencing leads to increased expression of IL-7 and IL-4 receptors and enhanced JAK-STAT pathway activation, consistent with loss of SOCS5's negative regulatory function.

Additional evidence for tumor suppressive function comes from studies showing that microRNA-9, which is elevated in some tumors, directly targets SOCS5 mRNA for degradation, resulting in enhanced JAK1/2 and STAT1/3 phosphorylation in endothelial cells [trengove-2013-socs-review-abstract]. By positioning SOCS5 as a regulator of multiple oncogenic signaling pathways, these studies suggest that restoration of SOCS5 expression could represent a therapeutic strategy in cancers characterized by SOCS5 silencing.

Open Questions

Several important questions regarding SOCS5 function remain to be addressed:

1. Mechanism of JAK inhibition: While SOCS5 clearly inhibits JAK1 and JAK2, the precise molecular mechanism remains unclear. Unlike SOCS1 and SOCS3, SOCS5 lacks a canonical KIR domain, and the contribution of different N-terminal regions to JAK selectivity has not been fully characterized.

2. SOCS4/SOCS5 functional redundancy: The lack of an overt phenotype in SOCS5 knockout mice may reflect compensation by SOCS4. Generation and characterization of SOCS4/SOCS5 double knockout mice would be essential to understand the true physiological requirements for these proteins.

3. Structural characterization: While one NMR structure of SOCS5 domains exists in the Protein Data Bank, full-length structural analysis and characterization of SOCS5 in complex with its targets (JAK, EGFR, Shc-1) would provide important mechanistic insights.

4. Substrate selectivity: The full range of SOCS5 substrates beyond EGFR, Shc-1, and IL-4R remains to be determined. Proteomics approaches could identify additional binding partners and substrates for ubiquitination.

5. Tissue-specific functions: The high expression of SOCS5 in brain suggests potential neural-specific functions that have not been fully explored. The role of SOCS5 in regulating neuroinflammation during viral infection suggests it may be important in other neurological conditions.

6. Therapeutic targeting: Given the tumor suppressive function of SOCS5, strategies to restore or enhance SOCS5 expression in cancer may have therapeutic value. Conversely, understanding whether SOCS5 inhibition could enhance anti-viral or anti-tumor immune responses requires further investigation.

7. Regulation of SOCS5 expression: While epigenetic silencing has been documented, the physiological signals that regulate SOCS5 expression levels remain poorly characterized compared to other SOCS family members.

References

1. [linossi-2013-socs5-jak-shc1] Linossi EM, Chandrashekaran IR, Kolesnik TB, Murphy JM, Webb AI, Willson TA, Kedzierski L, Bullock AN, Babon JJ, Norton RS, Nicola NA, Nicholson SE. Suppressor of Cytokine Signaling (SOCS) 5 Utilises Distinct Domains for Regulation of JAK1 and Interaction with the Adaptor Protein Shc-1. PLoS One. 2013 Aug 26;8(8):e70536. PMID: 23990909; PMCID: PMC3749136; DOI: 10.1371/journal.pone.0070536. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC3749136/

2. [nicholson-2005-socs5-egfr] Nicholson SE, Metcalf D, Sprigg NS, Columbus R, Walker F, Silva A, Cary D, Willson TA, Zhang JG, Hilton DJ, Alexander WS, Nicola NA. Suppressor of cytokine signaling (SOCS)-5 is a potential negative regulator of epidermal growth factor signaling. Proc Natl Acad Sci USA. 2005 Feb 15;102(7):2328-33. PMID: 15695332; PMCID: PMC549009; DOI: 10.1073/pnas.0409675102. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC549009/

3. [seki-2002-socs5-il4-stat6] Seki Y, Hayashi K, Matsumoto A, Seki N, Tsukada J, Ransom J, Naka T, Kishimoto T, Yoshimura A, Kubo M. Expression of the suppressor of cytokine signaling-5 (SOCS5) negatively regulates IL-4-dependent STAT6 activation and Th2 differentiation. Proc Natl Acad Sci USA. 2002 Sep 17;99(20):13003-8. PMID: 12242343; PMCID: PMC130576; DOI: 10.1073/pnas.202477099. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC130576/

4. [kedzierski-2017-socs5-influenza] Kedzierski L, Tate MD, Hsu AC, Kolesnik TB, Linossi EM, Dagley L, Dong Z, Freeman S, Infusini G, Starkey MR, Bird NL, Chatfield SM, Babon JJ, Huntington N, Belz G, Webb A, Wark PAB, Nicola NA, Xu J, Kedzierska K, Hansbro PM, Nicholson SE. Suppressor of cytokine signaling (SOCS)5 ameliorates influenza infection via inhibition of EGFR signaling. eLife. 2017 Jan 6;6:e20444. DOI: 10.7554/eLife.20444. URL: https://elifesciences.org/articles/20444

5. [brender-2004-socs5-lymphocyte] Brender C, Columbus R, Metcalf D, Handman E, Starr R, Huntington N, Tarlinton D, Ødum N, Nicholson SE, Nicola NA, Hilton DJ, Alexander WS. SOCS5 Is Expressed in Primary B and T Lymphoid Cells but Is Dispensable for Lymphocyte Production and Function. Mol Cell Biol. 2004 Jul;24(13):6094-103. PMID: 15199163; PMCID: PMC480873; DOI: 10.1128/MCB.24.13.6094-6103.2004. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC480873/

6. [kedzierski-2022-socs5-alphavirus] Kedzierski L, Tan AEQI, Foo IJH, Nicholson SE, Fazakerley JK. Suppressor of Cytokine Signalling 5 (SOCS5) Modulates Inflammatory Responses during Alphavirus Infection. Viruses. 2022 Nov 9;14(11):2476. PMID: 36366574; PMCID: PMC9692489; DOI: 10.3390/v14112476. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC9692489/

7. [trengove-2013-socs-review] Trengove MC, Ward AC. SOCS proteins in development and disease. Am J Clin Exp Immunol. 2013 Feb 27;2(1):1-29. PMID: 23885323; PMCID: PMC3714205. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC3714205/

8. [sharma-2019-socs5-tall] Sharma ND, Nickl CK, Kang H, et al. Epigenetic silencing of SOCS5 potentiates JAK-STAT signaling and progression of T-cell acute lymphoblastic leukemia. Cancer Sci. 2019 Jun;110(6):1931-1946. PMID: 30974024; PMCID: PMC6549933; DOI: 10.1111/cas.14021. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC6549933/

9. [sondergaard-2016-cullin5-review] Sondergaard JN, et al. The role of cullin 5-containing ubiquitin ligases. Cell Div. 2016 Mar 29;11:5. PMID: 27030794; PMCID: PMC4812663; DOI: 10.1186/s13008-016-0016-3. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC4812663/

10. [chandrashekaran-2015-socs5-jir-structure] Chandrashekaran IR, Mohanty B, Linossi EM, Nicholson SE, Babon JJ, Norton RS, Dagley LF, Leung EWW, Murphy JM. NMR assignments and solution structure of the JAK interaction region of SOCS5. Biochemistry. 2015 Jul 21;54(28):4672-82. PMID: 26173083; DOI: 10.1021/acs.biochem.5b00619. PDB: 2N34. URL: https://www.rcsb.org/structure/2n34

11. [stec-2011-drosophila-socs] Stec WJ, Zeidler MP. Drosophila SOCS Proteins. J Signal Transduct. 2011;2011:894510. PMCID: PMC3238392; DOI: 10.1155/2011/894510. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC3238392/

Citations

1. brender-2004-socs5-lymphocyte-abstract.md
2. chandrashekaran-2015-socs5-jir-structure-abstract.md
3. kedzierski-2017-socs5-influenza-abstract.md
4. kedzierski-2022-socs5-alphavirus-abstract.md
5. linossi-2013-socs5-jak-shc1-abstract.md
6. nicholson-2005-socs5-egfr-abstract.md
7. seki-2002-socs5-il4-stat6-abstract.md
8. sharma-2019-socs5-tall-abstract.md
9. sondergaard-2016-cullin5-review-abstract.md
10. stec-2011-drosophila-socs-abstract.md
11. trengove-2013-socs-review-abstract.md

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Research report: Human SOCS5 (UniProt O75159)

Verification of identity and domains
- Symbol and name: SOCS5 (Suppressor of cytokine signaling 5), also known as CIS-6/CISH6, matches the target protein identity given. SOCS proteins share a central SH2 domain and a C‑terminal SOCS box that recruits Elongin B/C to assemble a Cullin‑5–Rbx2 E3 ubiquitin ligase (CRL5), consistent with the UniProt-annotated domains for SOCS5 (SH2 and SOCS box) (cianciulli2024inflammatoryskindiseases pages 3-5, pilling2017cullin5andsocs pages 25-28).
- Organism: Evidence cited below pertains to human SOCS proteins and SOCS5 function in mammalian systems; disease studies specifically use human tissues/cells or clinically relevant models (sun2024socs5targetedby pages 5-9, ghalehbaghi2024suppressorofcytokine pages 9-10, lynch2024unravellingthedruggability pages 13-15).
- Family/domain alignment: Reviews covering SOCS family architecture confirm SOCS5 carries the canonical SH2 and SOCS box; SOCS4/5 are particularly implicated in regulation of receptor tyrosine kinase (RTK) signaling, including EGFR, in addition to cytokine pathways (cianciulli2024inflammatoryskindiseases pages 3-5).

Key concepts and definitions (current understanding)
- SOCS5 is an intracellular adaptor/regulator that uses its SH2 domain to bind phosphotyrosine-bearing targets and its SOCS box to recruit CRL5 E3 ligase machinery, promoting ubiquitination and downregulation of signaling components; SOCS proteins can also inhibit JAK/STAT by receptor competition or JAK-association mechanisms. SOCS1/3 use an N‑terminal KIR to directly inhibit JAK catalytic activity; SOCS5 lacks a canonical KIR but negatively regulates cytokine signaling through receptor/JAK engagement and CRL5-mediated substrate ubiquitination (pilling2017cullin5andsocs pages 25-28, cianciulli2024inflammatoryskindiseases pages 3-5).
- Distinctive role in IL‑4/STAT6/Th subsets: SOCS5 associates with the IL‑4 receptor in a phosphorylation-independent manner to suppress STAT6 activation and Th2 differentiation; overexpression reduces Th2 development in vivo, positioning SOCS5 as a Th1-promoting/Th2-limiting factor (pilling2017cullin5andsocs pages 28-31, ghalehbaghi2024suppressorofcytokine pages 9-10).

Biochemical mechanism and pathway roles
- JAK/STAT inhibition modes: SOCS5 inhibits cytokine signaling by binding the IL‑4 receptor region and reducing downstream STAT6; mechanistically, SOCS proteins inhibit by (i) SH2-mediated competition at receptors, (ii) direct or indirect engagement with JAKs, and (iii) recruiting CRL5 via the SOCS box to ubiquitinate targets. SOCS5 shows evidence of negatively regulating JAK1/JAK2‑dependent outputs in context-specific settings, though without a KIR motif like SOCS1/3 (pilling2017cullin5andsocs pages 28-31, pilling2017cullin5andsocs pages 25-28, cianciulli2024inflammatoryskindiseases pages 3-5).
- CRL5 E3 ligase assembly: The SOCS box of SOCS5 binds Elongin B/C and couples to Cullin‑5/Rbx2, forming a CRL5 E3 ligase that promotes ubiquitination and proteasomal degradation of bound substrates, a central route for signal attenuation across the SOCS family (cianciulli2024inflammatoryskindiseases pages 3-5, pilling2017cullin5andsocs pages 25-28).
- RTK regulation: SOCS4/5 are reported to regulate EGF receptor signaling; SOCS5 has been proposed to interact with EGFR via a phosphorylation‑independent mechanism through its N‑terminus/SH2 framework, placing it at the interface of growth factor and cytokine pathways (cianciulli2024inflammatoryskindiseases pages 3-5).
- PI3K pathway crosstalk: SOCS5 binds Shc (pY317) via its SH2 domain and associates with PI3K (p85/p110); SOCS5 depletion increases PI3K levels, suggesting SOCS5 impacts PI3K abundance and signaling complexes (pilling2017cullin5andsocs pages 28-31).
- Th cell polarization and IL‑4 signaling: Clinical and mechanistic data in chronic rhinosinusitis support a role for SOCS5 in Th lineage balance, with SOCS5 expression linked to Th1/Th17 axes and suppression of Th2 polarization via IL‑4R/STAT6 inhibition (ghalehbaghi2024suppressorofcytokine pages 9-10).

Cellular localization and recruitment dynamics
- SOCS5 is a cytosolic adaptor that is recruited to activated receptors or signaling intermediates via its SH2 domain; SOCS family proteins then engage CRL5 via the SOCS box to ubiquitinate bound substrates. Such recruitment underlies attenuation of cytokine/RTK signaling at the plasma membrane and endosomal compartments, though precise live-cell dynamics for SOCS5 remain less characterized than for SOCS1/3 (pilling2017cullin5andsocs pages 25-28, cianciulli2024inflammatoryskindiseases pages 3-5).

Recent developments and latest research (2023–2024)
- Pulmonary hypertension (2024): In a hypoxia-induced pulmonary hypertension model and in hypoxia‑treated human pulmonary arterial smooth muscle cells (HPASMCs), SOCS5 levels decline, and functional studies show that SOCS5 overexpression suppresses HPASMC proliferation, migration, contraction, and intracellular Ca2+ signals while inhibiting JAK2/STAT3 phosphorylation; SOCS5 knockdown has opposite effects. Mechanistically, miR‑155‑5p targets SOCS5 in this axis. GEO analysis also supports reduced SOCS5 in PH patient lung tissue (GSE15197). This identifies a miR‑155‑5p/SOCS5/JAK2/STAT3 regulatory axis in PH (BMC Pulmonary Medicine, Jan 2024, doi:10.1186/s12890-024-02857-6; https://doi.org/10.1186/s12890-024-02857-6) (sun2024socs5targetedby pages 5-9, sun2024socs5targetedby pages 1-2).
- Chronic rhinosinusitis (2024): In a cross-sectional human study, SOCS5 levels (mRNA/protein) differed between CRSwNP/CRSsNP cohorts and controls; SOCS5 correlated with Th17 in CRSsNP, and SOCS3 rose in CRSwNP. Findings support SOCS5 as a modulator of Th polarization in airway inflammation and a potential stratification biomarker (Yale J Biol Med, Jun 2024, doi:10.59249/hzfn2950; https://doi.org/10.59249/hzfn2950) (ghalehbaghi2024suppressorofcytokine pages 9-10).
- Immunology and infection (2024): A contemporary review highlights human/mouse data showing SOCS5 expression in T and B cells, its contribution to antiviral defense (SOCS5 deficiency increases early influenza A viral loads and disease severity), and clinical correlations (lower SOCS5 in COPD associated with elevated IL‑1β/TNFα), reinforcing SOCS5’s roles across cytokine/IFN networks (Frontiers in Immunology, Nov 2024, doi:10.3389/fimmu.2024.1449397; https://doi.org/10.3389/fimmu.2024.1449397) (lynch2024unravellingthedruggability pages 13-15, lynch2024unravellingthedruggability pages 15-16).
- SOCS family structure-function (2024): A review focused on SOCS druggability and structural biology reiterates SOCS family domain architecture and CRL5 coupling, and notes SOCS5’s negative regulation of IL‑4 signaling with limited development of direct SOCS5 modulators to date (Frontiers in Immunology, Nov 2024, doi:10.3389/fimmu.2024.1449397; https://doi.org/10.3389/fimmu.2024.1449397) (lynch2024unravellingthedruggability pages 13-15).

Current applications and real‑world implementations
- Inflammation and airway disease: Evidence positions SOCS5 as a negative regulator of IL‑4/STAT6 and JAK2/STAT3‑dependent responses in human airway and vascular smooth muscle contexts, suggesting potential for SOCS5‑centric strategies (e.g., restoring SOCS5 or blocking miR‑mediated suppression) to modulate Th2‑skewed or STAT3‑driven pathology (sun2024socs5targetedby pages 5-9, ghalehbaghi2024suppressorofcytokine pages 9-10).
- Biomarker potential: SOCS5 expression patterns in chronic rhinosinusitis subtypes and COPD correlations (lower SOCS5 with higher IL‑1β/TNFα) point to potential biomarker roles for inflammatory disease stratification and possibly prognosis (ghalehbaghi2024suppressorofcytokine pages 9-10, lynch2024unravellingthedruggability pages 15-16).
- General SOCS therapeutics landscape: While clinical translation has focused more on SOCS1/3 KIR‑mimetic peptides and JAK inhibitors, druggability analyses place SOCS family members as emerging targets and potential E3 handles. For SOCS5 specifically, translation is earlier-stage, with mechanistic disease associations guiding target validation (cianciulli2024inflammatoryskindiseases pages 3-5, lynch2024unravellingthedruggability pages 13-15).

Expert opinions and analysis from authoritative sources
- Structural/biochemical consensus: Reviews conclude that SOCS proteins, including SOCS5, function via SH2‑guided substrate recognition and SOCS box‑mediated assembly of CRL5 E3 ligases, forming a conserved negative feedback on cytokine/RTK signals. SOCS4/5’s prominence in EGFR/RTK pathways differentiates them functionally from SOCS1/3’s direct JAK blockade (cianciulli2024inflammatoryskindiseases pages 3-5, pilling2017cullin5andsocs pages 25-28).
- Immunology perspective: Contemporary immunology review emphasizes SOCS5’s modulation of adaptive (Th polarization, IL‑4 axis) and innate/antiviral responses, with disease-relevant observations in COPD and viral infection models. The review also flags a relative paucity of SOCS5-targeted drug development compared with SOCS1/3 (lynch2024unravellingthedruggability pages 13-15, lynch2024unravellingthedruggability pages 15-16).

Relevant statistics and data
- Pulmonary hypertension model: In vivo hypoxia (4 weeks) increased RVSP and RVHI significantly versus normoxia, concomitant with decreased lung SOCS5 protein; in HPASMCs, SOCS5 overexpression reduced proliferation/migration/contraction and JAK2/STAT3 phosphorylation, while SOCS5 knockdown had opposite effects. SOCS5 mRNA showed a biphasic response to hypoxia (early increase at 3–6 h, decrease at 12–72 h), aligning with protein dynamics; GEO GSE15197 analysis showed reduced SOCS5 in PH patient lungs (BMC Pulmonary Medicine, Jan 2024; https://doi.org/10.1186/s12890-024-02857-6) (sun2024socs5targetedby pages 5-9, sun2024socs5targetedby pages 1-2).
- Chronic rhinosinusitis cohort: SOCS3 protein increased in CRSwNP vs CRSsNP and controls (p<0.05 to p<0.001), and SOCS5 levels differed between CRSsNP and controls with correlations to Th17 markers; data support differential SOCS expression across CRS endotypes (Yale J Biol Med, Jun 2024; https://doi.org/10.59249/hzfn2950) (ghalehbaghi2024suppressorofcytokine pages 9-10).

Open questions and limits
- Direct structural biochemistry of SOCS5 engagement with specific human receptors (e.g., IL‑4R cytosolic regions and EGFR) and definitive CRL5-dependent substrates remain areas for deeper mechanistic mapping in human systems compared with SOCS1/3. Live‑cell recruitment/localization kinetics for SOCS5 are less well resolved (cianciulli2024inflammatoryskindiseases pages 3-5, pilling2017cullin5andsocs pages 25-28).

References (URLs and dates)
- Cianciulli A et al., Cells, Mar 2024. “Inflammatory Skin Diseases: Focus on the Role of Suppressors of Cytokine Signaling (SOCS) Proteins.” https://doi.org/10.3390/cells13060505 (cianciulli2024inflammatoryskindiseases pages 3-5).
- Pilling C. “Cullin5 and SOCS Protein Regulation of Receptor Tyrosine Kinases.” 2017. (general SOCS architecture and mechanisms) (pilling2017cullin5andsocs pages 25-28, pilling2017cullin5andsocs pages 28-31).
- Sun L et al., BMC Pulmonary Medicine, Jan 2024. “SOCS5, targeted by miR‑155‑5p, plays a negative regulatory role in pulmonary hypertension through inhibiting JAK2/STAT3 signaling pathway.” https://doi.org/10.1186/s12890-024-02857-6 (sun2024socs5targetedby pages 5-9, sun2024socs5targetedby pages 1-2).
- Ghalehbaghi B et al., Yale J Biol Med, Jun 2024. “Suppressor of Cytokine Signaling Proteins 3 and 5 Potentially Delineate Polarization of Th cells in Chronic Rhinosinusitis.” https://doi.org/10.59249/hzfn2950 (ghalehbaghi2024suppressorofcytokine pages 9-10).
- Lynch DM et al., Frontiers in Immunology, Nov 2024. “Unravelling the druggability and immunological roles of the SOCS-family proteins.” https://doi.org/10.3389/fimmu.2024.1449397 (lynch2024unravellingthedruggability pages 13-15, lynch2024unravellingthedruggability pages 15-16).

Conclusion
Human SOCS5 (UniProt O75159) is a SH2/SOCS‑box adaptor that attenuates cytokine and growth‑factor signaling by substrate recognition and CRL5‑mediated ubiquitination. Mechanistically, it suppresses IL‑4/STAT6 signaling and modulates JAK2/STAT3 outputs in disease settings, with emerging clinical associations in pulmonary hypertension and chronic rhinosinusitis, and correlations in COPD. While translational work has advanced more for SOCS1/3, recent analyses frame SOCS5 as a viable immuno‑regulatory target with potential therapeutic and biomarker applications, warranting focused efforts to define substrates, structural interfaces, and drugging strategies (cianciulli2024inflammatoryskindiseases pages 3-5, pilling2017cullin5andsocs pages 28-31, sun2024socs5targetedby pages 5-9, ghalehbaghi2024suppressorofcytokine pages 9-10, lynch2024unravellingthedruggability pages 13-15).

References

1. (cianciulli2024inflammatoryskindiseases pages 3-5): Antonia Cianciulli, Rosa Calvello, Chiara Porro, Dario Domenico Lofrumento, and Maria Antonietta Panaro. Inflammatory skin diseases: focus on the role of suppressors of cytokine signaling (socs) proteins. Cells, 13:505, Mar 2024. URL: https://doi.org/10.3390/cells13060505, doi:10.3390/cells13060505. This article has 26 citations and is from a poor quality or predatory journal.

2. (pilling2017cullin5andsocs pages 25-28): C Pilling. Cullin5 and socs protein regulation of receptor tyrosine kinases. Unknown journal, 2017.

3. (sun2024socs5targetedby pages 5-9): Lili Sun, Lihua Liu, Dongxue Liang, and Linlin Liu. Socs5, targeted by mir-155-5p, plays a negative regulatory role in pulmonary hypertension through inhibiting jak2/stat3 signaling pathway. BMC Pulmonary Medicine, Jan 2024. URL: https://doi.org/10.1186/s12890-024-02857-6, doi:10.1186/s12890-024-02857-6. This article has 3 citations and is from a peer-reviewed journal.

4. (ghalehbaghi2024suppressorofcytokine pages 9-10): Babak Ghalehbaghi, Hossein Aazami, Majid Khoshmirsafa, Alireza Mohebbi, Pegah Babaheidarian, Nesa Rashidi, Kobra Mokhtarian, Reza Ahmadi, Monireh Kamali, Majid Ponour, Ayda Sanaei, Farhad Seif, and Maryam Jalessi. Suppressor of cytokine signaling proteins 3 and 5 potentially delineate polarization of th cells in chronic rhinosinusitis. The Yale Journal of Biology and Medicine, 97:165-177, Jun 2024. URL: https://doi.org/10.59249/hzfn2950, doi:10.59249/hzfn2950. This article has 2 citations.

5. (lynch2024unravellingthedruggability pages 13-15): Dylan M. Lynch, Beth Forrester, Thomas Webb, and Alessio Ciulli. Unravelling the druggability and immunological roles of the socs-family proteins. Frontiers in Immunology, Nov 2024. URL: https://doi.org/10.3389/fimmu.2024.1449397, doi:10.3389/fimmu.2024.1449397. This article has 8 citations and is from a peer-reviewed journal.

6. (pilling2017cullin5andsocs pages 28-31): C Pilling. Cullin5 and socs protein regulation of receptor tyrosine kinases. Unknown journal, 2017.

7. (sun2024socs5targetedby pages 1-2): Lili Sun, Lihua Liu, Dongxue Liang, and Linlin Liu. Socs5, targeted by mir-155-5p, plays a negative regulatory role in pulmonary hypertension through inhibiting jak2/stat3 signaling pathway. BMC Pulmonary Medicine, Jan 2024. URL: https://doi.org/10.1186/s12890-024-02857-6, doi:10.1186/s12890-024-02857-6. This article has 3 citations and is from a peer-reviewed journal.

8. (lynch2024unravellingthedruggability pages 15-16): Dylan M. Lynch, Beth Forrester, Thomas Webb, and Alessio Ciulli. Unravelling the druggability and immunological roles of the socs-family proteins. Frontiers in Immunology, Nov 2024. URL: https://doi.org/10.3389/fimmu.2024.1449397, doi:10.3389/fimmu.2024.1449397. This article has 8 citations and is from a peer-reviewed journal.

Citations

1. cianciulli2024inflammatoryskindiseases pages 3-5
2. ghalehbaghi2024suppressorofcytokine pages 9-10
3. lynch2024unravellingthedruggability pages 13-15
4. lynch2024unravellingthedruggability pages 15-16
5. https://doi.org/10.1186/s12890-024-02857-6
6. https://doi.org/10.59249/hzfn2950
7. https://doi.org/10.3389/fimmu.2024.1449397
8. https://doi.org/10.3390/cells13060505
9. https://doi.org/10.3390/cells13060505,
10. https://doi.org/10.1186/s12890-024-02857-6,
11. https://doi.org/10.59249/hzfn2950,
12. https://doi.org/10.3389/fimmu.2024.1449397,

Introduction and Gene Family Background

Suppressor of Cytokine Signaling 5 (SOCS5) is a member of the SOCS family of intracellular adapter proteins that negatively regulate cytokine and growth factor signaling pathways (www.ncbi.nlm.nih.gov). Like other SOCS proteins, SOCS5 contains a central SH2 domain (Src homology 2) and a C-terminal SOCS box motif (www.ncbi.nlm.nih.gov). The SOCS family (also known as STAT-induced STAT inhibitors, SSI) is typically induced by cytokine signaling and acts in a classic negative feedback loop to dampen signal transduction (www.ncbi.nlm.nih.gov). Human SOCS5 (UniProt O75159), sometimes referred to as CIS6/CISH6, was initially less well characterized than SOCS1 or SOCS3, and early reports noted that its specific function was not fully determined (www.ncbi.nlm.nih.gov). However, accumulating evidence from targeted studies and recent reviews has begun to clarify SOCS5’s role as a modulator of immune signaling and cellular responses. Notably, SOCS5 is constitutively expressed in many cell types (especially in lymphoid and epithelial tissues) and can be further induced by specific stimuli (www.frontiersin.org) (www.frontiersin.org). It has emerged as a unique regulator within the SOCS family, with distinctive binding properties and context-dependent functions in signaling pathways. Below, we provide a detailed overview of SOCS5’s structure, mechanism of action, biological functions, subcellular localization, and involvement in key signaling pathways, drawing on recent research and authoritative sources.

Structural Features and Mechanism of Action

Structurally, SOCS5 follows the canonical architecture of SOCS family proteins. It possesses an N-terminal region of approximately 200 amino acids, a central SH2 domain, and a C-terminal SOCS box (www.ncbi.nlm.nih.gov). The SH2 domain enables SOCS5 to interact with specific tyrosine-phosphorylated targets, positioning it at activated receptor complexes. The SOCS box, in turn, serves as a recruitment module for an E3 ubiquitin ligase complex: it binds adaptor proteins (Elongin B/C) and links to Cullin-5/Rbx2, thereby targeting bound signaling proteins for ubiquitination and proteasomal degradation (www.frontiersin.org). In essence, SOCS5 acts as a substrate-recognition subunit of an E3 ubiquitin ligase, bringing the degradation machinery to activated cytokine/growth factor receptors or associated kinases and marking them for turnover (www.frontiersin.org). This mechanism is analogous across the SOCS family, although each member has distinct binding partners. Notably, unlike SOCS1 and SOCS3, which harbor a kinase inhibitory region (KIR) that can directly suppress kinase activity, SOCS5 lacks a canonical KIR motif (www.frontiersin.org). Thus, SOCS5 is thought to primarily exert its effects by sequestering targets and promoting their degradation rather than by enzymatically blocking kinase active sites.

One distinctive feature of SOCS5 is its ability to bind certain targets even in the absence of prior tyrosine phosphorylation. SOCS5 is reported to be the only SOCS family member known to inhibit a JAK–STAT pathway by binding to non-phosphorylated tyrosine motifs on a receptor (www.frontiersin.org). For example, SOCS5 can interact with the interleukin-4 receptor (IL-4R) via a region containing unphosphorylated tyrosine residues, an interaction that interferes with receptor signaling (detailed below) (www.frontiersin.org). In the context of Epidermal Growth Factor (EGF) signaling, structural models suggest SOCS5 can similarly bind to the activated EGF receptor complex and recognize target sites that may not require prior phosphorylation (www.frontiersin.org). This unique binding flexibility may allow SOCS5 to act as a “pre-emptive” brake on certain signaling pathways. Crystallographic and NMR studies support aspects of this mechanism: for instance, an NMR structure of the SOCS5 protein (the only SOCS solved by NMR to date) indicates that the long N-terminal region is intrinsically disordered except for a ~70-residue segment, suggesting the N-terminus may serve as a flexible tether or modulatory region (www.frontiersin.org). The conserved SH2 and SOCS box domains, however, form the functional core. A structural analysis of the SOCS4–Elongin B/C complex (SOCS4 is highly homologous to SOCS5) has revealed how the SOCS box engages the Cullin5 ubiquitin ligase and provided a molecular basis for SOCS-dependent EGF receptor degradation (www.frontiersin.org). By analogy, SOCS5 likely employs a similar SOCS box interface to recruit the ubiquitin ligase and target receptors like EGFR for degradation (www.frontiersin.org). In summary, the mechanism of SOCS5 involves recognition of signaling receptors or associated kinases through its SH2 domain (with an unusual capacity to bind some unphosphorylated sites) and the subsequent recruitment of ubiquitinating enzymes via the SOCS box, culminating in down-regulation of the signaling cascade.

Expression and Cellular Localization

SOCS5 is widely expressed in human tissues, with particularly notable levels in the immune system and certain epithelial tissues. Transcript profiling indicates ubiquitous expression, with higher mRNA levels reported in lymphoid organs such as spleen and lymph nodes, as well as in the brain and reproductive tissues (www.frontiersin.org) (www.ncbi.nlm.nih.gov). For example, in mice, SOCS5 is constitutively expressed in both T and B lymphocytes, and its mRNA is abundant in primary lymphoid organs (www.frontiersin.org). The resting brain also expresses high levels of SOCS5 mRNA (pmc.ncbi.nlm.nih.gov), an interesting finding given that most SOCS proteins are studied mainly in peripheral immune contexts. This widespread expression suggests SOCS5 may have housekeeping roles in regulating cytokine or growth factor signals across multiple cell types. Indeed, basal SOCS5 expression in the absence of overt stimulation hints that it could modulate signaling thresholds under normal conditions, not just in response to inflammation.

At the subcellular level, SOCS5 is an intracellular protein (predicted and observed to be localized in the cell interior (www.proteinatlas.org)). It lacks any signal peptide or transmembrane domain and thus is not secreted. In immunofluorescence analyses of cultured cells, SOCS5 is found primarily in the cytosol (www.proteinatlas.org). There is some evidence of additional localization to the plasma membrane and nucleoplasm in certain cell lines (www.proteinatlas.org), although the functional significance of nuclear localization is unclear (SOCS5 has no known nuclear localization signal, unlike SOCS7 which does (www.frontiersin.org)). It is likely that SOCS5 shuttles to the vicinity of activated receptor complexes at the inner plasma membrane when those receptors (e.g. cytokine receptors or EGFR) are stimulated. In support of this, immunohistochemical staining in tissues often shows SOCS5 within the cytoplasm of cells that are actively engaged in signaling. For instance, during influenza virus infection in mouse lungs, SOCS5 protein was detected in airway epithelial cells and its expression increased upon infection (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov), consistent with SOCS5 being induced and acting locally at the site of receptor signaling in those cells. Taken together, SOCS5 can be described as a cytosolic adaptor protein that functions at or near the cell membrane (where receptor signaling occurs) and possibly transiently in other compartments, to regulate intracellular signaling cascades. Its broad tissue expression underscores a potential to influence diverse biological processes, though the extent of its role may vary by cell type.

Function in Cytokine Signaling (JAK–STAT Pathways)

One of the primary contexts in which SOCS5 operates is the regulation of cytokine-driven JAK–STAT signaling, particularly the interleukin-4 (IL-4) pathway. IL-4 is a key Th2 cytokine that signals through the IL-4 receptor complex, activating JAK1/JAK3 tyrosine kinases and the transcription factor STAT6 (www.frontiersin.org). SOCS5 was first implicated as a negative regulator of IL-4 signaling in a landmark study by Seki et al. (2002). In that study, transgenic mice overexpressing SOCS5 in T cells were found to have blunted IL-4 responses: SOCS5 expression blocked IL-4–dependent phosphorylation of STAT6 and curtailed T-helper 2 (Th2) cell differentiation (www.frontiersin.org). In other words, forcing high levels of SOCS5 inhibited the ability of IL-4 to drive naïve T cells towards the Th2 lineage, indicating that SOCS5 can antagonize IL-4/STAT6 signaling. Mechanistically, SOCS5 was shown to bind to the IL-4 receptor α chain (IL4Rα). Notably, instead of the typical mode of an SH2 domain binding a phosphorylated tyrosine on the receptor, SOCS5 appears to bind IL4Rα at a particular region even before that site is phosphorylated (www.frontiersin.org). This binding interferes with the assembly of the signaling complex – specifically, evidence suggests SOCS5 binding to IL4Rα hinders the association of JAK1 with the receptor, thereby preventing JAK1 activation and downstream STAT6 phosphorylation (www.frontiersin.org) (www.frontiersin.org). By acting at this receptor-proximal step, SOCS5 effectively uncouples IL-4 receptor engagement from STAT6 activation.

The functional consequence of SOCS5’s interference in IL-4 signaling is a shift in T-cell response bias. Th2 differentiation is impaired when SOCS5 is active, tilting the balance toward Th1 responses under certain conditions (www.frontiersin.org). In the SOCS5 transgenic model, researchers observed reduced Th2 cytokine production and enhanced Th1-like responses, consistent with IL-4 signaling being held in check (www.frontiersin.org). This was evidenced by lower IL-4-driven IgG1/IgE production and higher IFN-γ (a Th1 cytokine) in those mice, aligning with the idea that SOCS5 promotes a Th1 bias by restraining IL-4/STAT6 signals (www.frontiersin.org). Importantly, the inhibitory effect of SOCS5 on IL-4 signaling could be overcome by high doses of IL-4 (www.frontiersin.org). When IL-4 levels were experimentally increased, they could largely bypass SOCS5’s blockade, suggesting that SOCS5 imposes a threshold or brake rather than an absolute block on the pathway. This nuance implies that SOCS5’s role is to fine-tune signaling sensitivity – moderate IL-4 stimuli might be dampened by SOCS5, whereas an overwhelmingly strong IL-4 stimulus can still drive STAT6 activation (albeit needing higher cytokine concentrations) (www.frontiersin.org).

Despite these clear effects in overexpression models, genetic knockout studies revealed that SOCS5 is not strictly required for normal immune cell development or baseline Th1/Th2 differentiation. Brender et al. (2004) generated SOCS5-deficient mice and found that these mice had normal lymphocyte development – for example, normal CD4^+ to CD8^+ T-cell ratios and no overt immune system abnormalities (www.frontiersin.org) (www.frontiersin.org). Naïve SOCS5^−/− mice did not show skewed Th1 vs Th2 immune polarization under resting conditions, likely due to compensation by other regulators (www.frontiersin.org) (www.frontiersin.org). Indeed, subsequent studies suggested that other SOCS family proteins (such as CIS, also known as CISH) can also modulate IL-4/STAT6 signaling and might partly compensate for the absence of SOCS5 (www.frontiersin.org). For instance, one analysis noted only a “marginal” inhibition of IL-4 signaling by SOCS5 alone and proposed that CIS (CISH) might share in the negative feedback of IL-4 signaling (www.frontiersin.org). This redundancy could explain why SOCS5-knockout T cells can still regulate Th2 responses unless challenged. However, under certain immune challenges or when IL-4 levels are limiting, the contribution of SOCS5 becomes evident in shaping the response. In summary, SOCS5’s role in cytokine signaling is as a modulatory brake on specific JAK–STAT pathways – most prominently IL-4/STAT6 – helping to calibrate T-cell differentiation and cytokine responses. Its loss does not abrogate these pathways due to compensatory mechanisms, but its presence provides an additional layer of control that can influence immune outcomes (for example, restraining overzealous Th2 responses that could lead to allergy or suboptimal anti-microbial defense).

Beyond IL-4, SOCS5 may interact with other cytokine signaling pathways, though these are less thoroughly characterized. High-throughput interaction studies and protein network analyses have hinted that SOCS5 could associate with components of the Type I interferon receptor (IFNAR) and the IL-23 receptor complexes (www.frontiersin.org). In a STRING network analysis, SOCS5 showed overlapping protein–protein interactions with SOCS1 and SOCS3, including connections to IFNAR1 (the interferon-α/β receptor subunit) and to IL-23α (a subunit of the IL-23 receptor) (www.frontiersin.org). This suggests SOCS5 might also play roles in interferon signaling or IL-23/Th17 pathways. However, direct functional evidence for SOCS5 in these pathways is still limited. It is worth noting that SOCS1 and SOCS3 are the dominant negative regulators for many cytokines (e.g. SOCS1 for IFN-γ/STAT1 and SOCS3 for IL-6/STAT3), whereas SOCS5’s influence seems more specialized, primarily affecting IL-4/STAT6, and possibly certain growth factor signals (discussed next). Any contribution of SOCS5 to IFN or IL-12/IL-23 signaling likely emerges in specific contexts or cell types and remains an area for further investigation (www.frontiersin.org).

Role in EGF Receptor Signaling and Other Growth Factor Pathways

Besides cytokines, SOCS5 has been implicated in the regulation of growth factor signaling, most prominently the Epidermal Growth Factor receptor (EGFR) pathway. This was first reported by Nicholson et al. (2005), who identified SOCS5 as a potential negative regulator of EGF signaling (pmc.ncbi.nlm.nih.gov). In that study, and subsequent experiments, SOCS5 was shown to associate with the EGFR and attenuate its signaling output. The mechanism is analogous to cytokine receptor regulation: SOCS5’s SH2 domain binds to the EGFR or its upstream signaling complex (likely at specific tyrosine sites on EGFR or associated docking proteins), and the SOCS box then recruits the ubiquitin ligase complex. As a result, SOCS5 promotes the degradation or downregulation of EGFR on the cell surface (www.frontiersin.org). Indeed, both SOCS4 and SOCS5 are unique among the SOCS family in their ability to markedly reduce cellular EGFR levels and dampen EGF-induced signaling (www.frontiersin.org). Experimental evidence in cell models supports that overexpression of SOCS5 leads to decreased EGFR protein levels and blunted activation of downstream pathways (such as the PI3K–AKT and MAPK pathways) upon EGF stimulation (www.frontiersin.org) (www.frontiersin.org). An X-ray crystal structure of the SOCS4–elongin B/C complex (with homology to SOCS5) provided insight into this process, revealing how SOCS proteins interface with elongin/Cullin complexes and recognize EGFR cytoplasmic tails, thereby mediating EGFR ubiquitination and subsequent degradation (www.frontiersin.org). By targeting EGFR in this way, SOCS5 effectively serves as a feedback inhibitor in cells where EGFR signaling intersects with STAT activation – for example, EGF can activate STAT1/3/5, inducing SOCS gene expression (www.frontiersin.org), which then feeds back to limit the EGFR itself (a built-in tumor-suppressive mechanism in principle).

Functionally, the ability of SOCS5 to restrain EGFR signaling has important implications. EGFR signaling must be tightly regulated, as aberrant activation of EGFR contributes to oncogenesis in many epithelial cancers (www.frontiersin.org). By downregulating EGFR, SOCS5 could act as a tumor suppressor in tissues where EGFR-driven proliferation needs to be checked. Consistently, loss or silencing of SOCS5 has been associated with prolonged EGFR signaling in some models, whereas enhancing SOCS5 leads to reduced EGF responsiveness (www.frontiersin.org) (www.frontiersin.org). A concrete in vivo illustration of SOCS5’s impact on EGFR comes from infectious disease research: an eLife 2017 study found that SOCS5 plays a crucial role in lung epithelial cells during influenza virus infection by targeting EGFR. In that study, SOCS5-deficient mice were highly susceptible to influenza, and the underlying cause was traced to excessive EGFR/PI3K signaling in the airways (pmc.ncbi.nlm.nih.gov). Normally, influenza infection in lung epithelial cells induces SOCS5 expression, which then helps inhibit EGFR signaling early in infection (pmc.ncbi.nlm.nih.gov). EGFR activity can be proviral (the virus can hijack EGFR-mediated PI3K signaling to enhance its replication or to delay cell death). In SOCS5 knockout lungs, EGFR signaling went unchecked, leading to higher PI3K/Akt activation and a cellular environment more permissive for viral replication (pmc.ncbi.nlm.nih.gov). As a result, viral titers in SOCS5^−/− mice were significantly higher, and the mice experienced more severe disease (pmc.ncbi.nlm.nih.gov) (www.frontiersin.org). Pharmacologically blocking PI3K in those mice partially mitigated the viral spread, underscoring that the protective effect of SOCS5 during influenza infection was largely through EGFR–PI3K pathway inhibition (pmc.ncbi.nlm.nih.gov). This finding linked SOCS5’s biochemical role at the receptor level to a tangible physiological outcome (antiviral defense).

It is worth noting that SOCS5’s effect on EGFR may also intersect with JAK–STAT signaling. EGFR activation can trigger multiple downstream pathways: RAS/MAPK, PI3K/Akt, and also STAT signaling in some contexts (www.frontiersin.org). By curbing EGFR, SOCS5 indirectly influences these pathways. In particular, STAT3 activity (often downstream of EGFR in tumors) might be modulated by SOCS5 presence. Some studies have observed that introducing SOCS5 into cancer cell lines inhibits EGF-induced STAT3 phosphorylation and cell migration, supporting its role as an EGFR pathway suppressor (these data are in line with Nicholson et al.’s initial report) (pmc.ncbi.nlm.nih.gov). Therefore, in the realm of growth factors, SOCS5 functions comparably to how it does in cytokine pathways: it binds to activated receptors (here, EGFR) and recruits ubiquitin-mediated negative feedback, thus preventing overactivation of proliferative and survival signals. This cross-talk between cytokine signaling regulators and growth factor pathways highlights the integrative role SOCS proteins can play in cell signaling networks.

Immunological Role and Response to Infection

Given its role in regulating cytokine signaling, SOCS5 is an important modulator of immune responses. Its influence can be seen in how the immune system responds to pathogens, where precise regulation of cytokine signaling is critical. Experimental infection models have revealed that SOCS5 helps strike a balance between effective pathogen defense and preventing excessive inflammation. Several recent studies, particularly in the last few years, have shed light on SOCS5’s function during viral infections:

• Influenza Virus (innate lung immunity): As noted above, SOCS5 has a protective role in influenza infection. In a 2017 study (Kedzierski et al., eLife 2017), mice lacking SOCS5 (Socs5^−/−) were more susceptible to Influenza A virus. After infection with H1N1 influenza, Socs5^−/− mice showed accelerated weight loss, higher viral loads in the lungs, and elevated pro-inflammatory cytokines compared to wild-type mice (www.frontiersin.org). By day 3 post-infection, SOCS5-knockout mice had lost significantly more body weight (~20% vs ~10% in controls) and harbored greater pulmonary viral titers (www.frontiersin.org). Notably, even at very early times (day 1 post-infection), viral levels were elevated in SOCS5-deficient lungs, before adaptive immunity kicks in (www.frontiersin.org). This suggested an impaired innate ability to restrict early viral replication in the absence of SOCS5 (www.frontiersin.org). The mechanism was linked to uncontrolled EGFR/PI3K signaling in airway epithelial cells, as mentioned: without SOCS5, infected epithelial cells likely experienced heightened EGFR activation, which is known to facilitate influenza virus entry or replication. Conversely, in wild-type mice, SOCS5 induction during infection constrained EGFR signaling, thereby limiting the virus. Supporting this, the authors found that restoring SOCS5 in lung epithelial cells curtailed influenza virus growth, and patients with chronic obstructive pulmonary disease (COPD) – who often have more severe flu – exhibited inappropriately low SOCS5 induction during flu infection (pmc.ncbi.nlm.nih.gov) (www.frontiersin.org). In primary human airway epithelial cells from healthy individuals, influenza infection upregulated SOCS5 expression, whereas cells from COPD patients failed to upregulate SOCS5 and suffered higher viral replication (pmc.ncbi.nlm.nih.gov). This implies SOCS5 is a critical factor in early anti-influenza defense, and its deficiency or dysfunction (as in COPD lungs) may predispose to viral susceptibility. These findings are so salient that the authors proposed therapeutic strategies to boost SOCS5 activity in airway epithelium as a novel means to protect high-risk patients from influenza (pmc.ncbi.nlm.nih.gov).

• Alphavirus (neuroinflammation in encephalitis): A more recent study examined SOCS5 in the context of viral brain infection. Lukasz Kedzierski and colleagues (2022) used a mouse model of encephalitis caused by Semliki Forest Virus (an alphavirus) to investigate SOCS5’s role in the central nervous system (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). The brain is an immunologically sensitive site where excessive inflammation can be devastating. Intriguingly, SOCS5 is highly expressed in the resting brain (pmc.ncbi.nlm.nih.gov), but its function there was previously unknown. In the SFV infection model, SOCS5-knockout mice experienced worse clinical outcomes despite viral loads being similar or even lower than in wild-type mice early on. By 4 days post-infection, SOCS5^−/− mice actually had somewhat lower virus titers in the brain than wild-type (indicating their immune response initially controlled the virus effectively, possibly because it was hyperactivated) (pmc.ncbi.nlm.nih.gov). However, the SOCS5^−/− mice showed significantly greater weight loss and severe neuroinflammation as the infection progressed (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Histological and immunological analysis revealed increased infiltration of inflammatory cells (CD11b^+ myeloid cells) and higher levels of cytokines/chemokines in the brains of SOCS5-deficient mice (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). The heightened inflammation, rather than uncontrolled viral replication, was the driver of pathology. These results led to the conclusion that SOCS5 is a vital regulator of antiviral immunity in the CNS, primarily by suppressing excessive inflammatory responses that can cause neuropathology (pmc.ncbi.nlm.nih.gov). In other words, SOCS5 in the brain acts as a check on the immune response, ensuring that the anti-viral reaction does not become too damaging to neural tissue. Without SOCS5, the antiviral response overshoots, causing immunopathology (even though the virus itself was being cleared). This paints a complementary picture to the influenza scenario: in the lung epithelium, SOCS5’s main benefit was to limit the virus (a direct antiviral effect via EGFR inhibition), whereas in the brain, SOCS5’s benefit was to limit the host’s own inflammatory damage (an immunomodulatory effect). In both cases, SOCS5 helps maintain a critical balance during infection – promoting enough immunity to control the pathogen, but preventing excessive signaling that could harm the host.

• Other viral infections: Additional studies have implicated SOCS5 in responses to various viruses. For instance, SOCS5 has been reported to influence type I interferon (IFN) responses during certain infections. In a chicken model of infectious bursal disease virus, and in feline herpesvirus infection models, changes in SOCS5 expression were correlated with alterations in IFN-β production and antiviral states (pmc.ncbi.nlm.nih.gov). These suggest that SOCS5 might modulate interferon signaling pathways (consistent with the idea it could interact with IFNAR as mentioned earlier). Another intriguing observation comes from Japanese Encephalitis Virus (JEV) studies in vitro: JEV infection upregulated SOCS5 in human microglial cells but downregulated SOCS5 in mouse neuronal cells, and in both cases this was associated with enhanced viral replication (pmc.ncbi.nlm.nih.gov). One interpretation is that viruses may manipulate host SOCS5 levels to their advantage – e.g., a virus might induce SOCS5 in an immune cell to suppress that cell’s antiviral cytokine response (facilitating infection), or conversely suppress SOCS5 in a neuron to remove a brake on a proviral signaling pathway. While the details vary, the common theme is that SOCS5 is a node in the virus-host interaction network, capable of tipping the balance of signaling pathways that either promote or restrain viral replication and the immune reaction. In sum, SOCS5’s immunological role is context-dependent: it can act as an antiviral factor in some settings by inhibiting signaling pathways the virus needs (like EGFR/PI3K in flu), or as an anti-inflammatory guardian by preventing immune overreaction (like in viral encephalitis). The net effect of SOCS5 during any given infection likely depends on which signaling axes are most pathogenic if left unregulated.

Implications in Disease and Therapeutic Potential

Considering its regulatory functions in key signaling pathways, SOCS5 has been examined in the context of various diseases. Changes in SOCS5 expression or function can contribute to pathological conditions, especially those involving aberrant cytokine signaling or growth factor activity. Below we highlight several areas where SOCS5 dysregulation has been linked to disease, along with expert analyses:

• Inflammatory and Autoimmune Diseases: Because SOCS5 modulates cytokine signaling (like IL-4 and possibly IFNs), it has potential relevance in immune-mediated disorders. Recent evidence suggests associations between SOCS5 and diseases such as autoimmune uveoretinitis, multiple sclerosis (MS), and type 1 diabetes (T1D) (www.frontiersin.org). For example, in experimental autoimmune uveoretinitis (an inflammatory eye condition) and in MS models, altered expression of SOCS5 has been observed in immune cells infiltrating target tissues (though the exact causal role is still under study). One hypothesis is that lower SOCS5 levels could permit stronger Th2 or other pathologic cytokine responses, exacerbating inflammation in autoimmune conditions. Conversely, higher SOCS5 might tilt the immune balance and potentially be protective or, in some cases, detrimental if it skews responses improperly. In T1D, which involves destruction of pancreatic islet cells by the immune system, cytokine signaling (like IFN-γ and IL-1) is crucial; any polymorphism or epigenetic change reducing SOCS5 could lead to hyperactive cytokine signaling and contribute to disease progression. These connections remain mostly correlative for now, but ongoing research is probing whether SOCS5 could be a therapeutic target – for instance, could enhancing SOCS5 in certain immune cells ameliorate autoimmune pathology by damping harmful cytokine cascades? As of 2024, SOCS5 is recognized as part of the complex regulatory network in autoimmunity, with emerging evidence of its involvement, as summarized by Lynch et al. (2024) (www.frontiersin.org). Further studies (including the use of SOCS5-knockout mice in autoimmune models) are needed to pinpoint its precise role in these diseases.

• Cancer: Tumor Suppressor and Oncogenic Roles (Context-Dependent): The relationship between SOCS5 and cancer is nuanced. On one hand, by virtue of inhibiting growth and survival signals (like those from EGFR and certain cytokines), SOCS5 can function as a tumor suppressor. This is evident in some hematological cancers: for instance, in T-cell acute lymphoblastic leukemia (T-ALL), epigenetic silencing of the SOCS5 gene has been documented and is associated with enhanced JAK–STAT signaling (www.frontiersin.org). A 2019 study by Sharma et al. found that methylation and downregulation of SOCS5 in T-ALL cells led to hyperactivation of the JAK/STAT pathway and uncontrolled cell proliferation (www.frontiersin.org). Restoration of SOCS5 in these leukemic cells attenuated STAT signaling and slowed tumor cell growth, suggesting that SOCS5 normally acts as a brake on cytokine-driven leukemogenesis. The authors concluded that loss of SOCS5 accelerates leukemia progression by unleashing pro-proliferative signaling (notably, many T-ALL cases involve aberrant IL-7/IL-7R signaling, which could be kept in check by SOCS5) (www.frontiersin.org). This positions SOCS5 as a potential tumor suppressor gene in T-cell leukemia, and indeed, components of the JAK–STAT pathway are being targeted therapeutically in such cancers (raising the question of whether SOCS5 mimetics or gene reactivation strategies might have a place in treatment).

In solid tumors, one might expect a similar tumor-suppressive role where EGFR or cytokine signaling drives cancer. For example, since SOCS5 can degrade EGFR, its loss could conceivably contribute to EGFR overexpression in cancers like lung or head & neck cancers. Some cancer profiling studies have found low SOCS5 expression or deletions in subsets of epithelial tumors, correlating with worse prognosis, consistent with a suppressor function (though this varies by cancer type). Paradoxically, more recent findings reveal that SOCS5 can also have pro-oncogenic effects in certain contexts. A striking example is in hepatocellular carcinoma (HCC) with underlying liver steatosis (fatty change). A 2023 study by Wang et al. examined a subset of HCC characterized by fatty liver disease and high lipogenesis, and identified SOCS5 as a driver of tumor metastasis in this context (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). They found that SOCS5 was upregulated in steatotic HCC tumors (with HBV cirrhosis) compared to non-steatotic tumors, and high SOCS5 expression correlated with increased de novo fatty acid synthesis and more aggressive tumor phenotypes (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Mechanistically, SOCS5 was shown to form a complex with an RNA-binding protein called RBMX, via its SH2 domain binding to RBMX’s RNA-recognition motif, and this complex co-activated the sterol regulatory element-binding protein 1 (SREBP1), a master regulator of lipid synthesis (pmc.ncbi.nlm.nih.gov). The SOCS5–RBMX interaction (critically dependent on SOCS5’s SH2 domain residues Y413 and D443) boosted the transcription of lipogenic enzymes, leading to lipid accumulation in cancer cells and promotion of metastasis (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). In functional assays, knocking down SOCS5 reduced lipid synthesis and impeded HCC cell invasion, whereas overexpressing SOCS5 enhanced these malignant traits (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This surprising finding shows that SOCS5, beyond its classical role in cytokine inhibition, can moonlight in other pathways (here, metabolic gene regulation) to favor tumor progression. The context – a steatotic, inflammatory liver environment – likely provides cytokine and growth signals that induce SOCS5, but the cancer co-opts SOCS5 for an advantage. It underlines that SOCS5’s impact on cancer can be double-edged: in some cancers it is beneficial to the host to have SOCS5 (to restrain growth signals), whereas in others the cancer finds a way to utilize SOCS5 to further its malignancy.

These findings have therapeutic implications. In cancers where SOCS5 is silenced (e.g. T-ALL or possibly some solid tumors), therapies that re-activate SOCS5 or mimic its function could suppress tumor-promoting signaling. Conversely, in cancers like the steatotic HCC subset, inhibiting the aberrant SOCS5 interaction (for instance, blocking SOCS5’s SH2 domain from binding RBMX or other partners) might hinder the tumor’s metastatic drive (pmc.ncbi.nlm.nih.gov). Such context-dependent strategies exemplify the precision needed in targeting SOCS proteins. As of now, no drugs directly targeting SOCS5 are in clinical use, but the druggability of SOCS family proteins is a topic of growing interest (www.frontiersin.org). The large interface of the SOCS SH2 domain and its peptide binding groove could be targeted by small molecules or stabilized peptides to either inhibit or enhance specific interactions. In fact, proof-of-concept came from SOCS1: a peptide mimicking a phosphotyrosine site of JAK2 was used to competitively inhibit SOCS1, thereby boosting immune responses in preclinical models (www.frontiersin.org). By analogy, one could foresee small molecules that disrupt SOCS5’s recruitment of its targets (or its assembly of the ubiquitin ligase complex) as potential modulators of the pathways SOCS5 controls. Any such therapeutic approach would require careful calibration to avoid unintended suppression or hyperactivation of immune signals, given SOCS5’s balancing role.

In summary, SOCS5 is emerging as an important regulatory protein in human health and disease. Its activity influences the outcome of cytokine signaling in immunity, the intensity of inflammatory reactions, and the tone of growth factor signaling in both normal and malignant cells. Authoritative reviews in 2023–2024 emphasize that SOCS5 has been relatively understudied compared to other SOCS members (www.frontiersin.org), but recent research is illuminating its diverse roles. The consensus from experts is that SOCS5 helps maintain immune homeostasis – for instance, by tempering IL-4-driven Th2 responses and preventing immunopathology during infections (www.frontiersin.org) (www.frontiersin.org). When this regulation is lost (as in SOCS5 knockout mice or in diseases where SOCS5 is downregulated), the consequences can be seen as either unchecked signaling (leading to excessive inflammation or cell proliferation) or, conversely, loss of a protective brake on pathogens. Conversely, aberrant upregulation of SOCS5 in the wrong context can contribute to disease, as seen in certain cancers. Going forward, a deeper understanding of SOCS5’s precise molecular interactions (e.g. identifying all its binding partners and target substrates in various cell types) will be crucial. This will not only clarify how SOCS5 exerts its effects in different signaling pathways but also point to whether SOCS5 can be manipulated for therapeutic benefit. Already, the research community is considering SOCS5 as a potential target – for example, boosting SOCS5 activity in lung epithelium as an antiviral strategy (pmc.ncbi.nlm.nih.gov), or inhibiting SOCS5’s novel oncogenic partnership in HCC (pmc.ncbi.nlm.nih.gov). Such applications are speculative but grounded in the mechanistic insights gained so far. In conclusion, SOCS5 serves as a multifaceted adaptor that fine-tunes critical signaling networks within cells. It ensures that cytokine and growth factor signals are neither too weak (to mount proper responses) nor too strong (to avoid pathological outcomes), underscoring its importance in maintaining the delicate balance of physiological signaling. Each new discovery – whether in immunology, virology, or oncology – adds a piece to the puzzle of SOCS5’s function, and collectively these findings enhance our ability to annotate this gene with confidence in its role in human biology.

References: (Key sources are cited in-line above with publication year and link)

Citations

1. AnnotationURLCitation(end_index=342, start_index=223, title='SOCS5 suppressor of cytokine signaling 5 [Homo sapiens (human)] - Gene - NCBI', type='url_citation', url='https://www.ncbi.nlm.nih.gov/gene/9655#:~:text=The%20protein%20encoded%20by%20this,Expression')
2. AnnotationURLCitation(end_index=574, start_index=455, title='SOCS5 suppressor of cytokine signaling 5 [Homo sapiens (human)] - Gene - NCBI', type='url_citation', url='https://www.ncbi.nlm.nih.gov/gene/9655#:~:text=The%20protein%20encoded%20by%20this,Expression')
3. AnnotationURLCitation(end_index=879, start_index=760, title='SOCS5 suppressor of cytokine signaling 5 [Homo sapiens (human)] - Gene - NCBI', type='url_citation', url='https://www.ncbi.nlm.nih.gov/gene/9655#:~:text=The%20protein%20encoded%20by%20this,Expression')
4. AnnotationURLCitation(end_index=1202, start_index=1083, title='SOCS5 suppressor of cytokine signaling 5 [Homo sapiens (human)] - Gene - NCBI', type='url_citation', url='https://www.ncbi.nlm.nih.gov/gene/9655#:~:text=The%20protein%20encoded%20by%20this,Expression')
5. AnnotationURLCitation(end_index=1694, start_index=1526, title='Frontiers | Unravelling the druggability and immunological roles of the SOCS-family proteins', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1449397/full#:~:text=SOCS5%20expression%20is%20constitutive%20in,99')
6. AnnotationURLCitation(end_index=1864, start_index=1695, title='Frontiers | Unravelling the druggability and immunological roles of the SOCS-family proteins', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1449397/full#:~:text=Figure%C2%A06,A%20legend%20explaining%20protein')
7. AnnotationURLCitation(end_index=2608, start_index=2489, title='SOCS5 suppressor of cytokine signaling 5 [Homo sapiens (human)] - Gene - NCBI', type='url_citation', url='https://www.ncbi.nlm.nih.gov/gene/9655#:~:text=The%20protein%20encoded%20by%20this,Expression')
8. AnnotationURLCitation(end_index=3178, start_index=2994, title='Frontiers | Unravelling the druggability and immunological roles of the SOCS-family proteins', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1449397/full#:~:text=SOCS%20box%20domain,SOCS3%2C%20house%20a%20kinase%20inhibitory')
9. AnnotationURLCitation(end_index=3582, start_index=3398, title='Frontiers | Unravelling the druggability and immunological roles of the SOCS-family proteins', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1449397/full#:~:text=SOCS%20box%20domain,SOCS3%2C%20house%20a%20kinase%20inhibitory')
10. AnnotationURLCitation(end_index=4036, start_index=3849, title='Frontiers | Unravelling the druggability and immunological roles of the SOCS-family proteins', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1449397/full#:~:text=is%20not%20known%20to%20contain,for%20the%20SOCS%20protein%20only')
11. AnnotationURLCitation(end_index=4651, start_index=4490, title='Frontiers | Unravelling the druggability and immunological roles of the SOCS-family proteins', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1449397/full#:~:text=Th2%20cell%20development%20and%20the,34')
12. AnnotationURLCitation(end_index=5018, start_index=4857, title='Frontiers | Unravelling the druggability and immunological roles of the SOCS-family proteins', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1449397/full#:~:text=Th2%20cell%20development%20and%20the,34')
13. AnnotationURLCitation(end_index=5447, start_index=5238, title='Frontiers | Unravelling the druggability and immunological roles of the SOCS-family proteins', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1449397/full#:~:text=turn%20activates%20multiple%20STAT%20proteins,to%20affect%20this%20signalling%20cascade')
14. AnnotationURLCitation(end_index=6071, start_index=5900, title='Frontiers | Unravelling the druggability and immunological roles of the SOCS-family proteins', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1449397/full#:~:text=SOCS4%20contains%20a%20considerably%20longer,EGFR')
15. AnnotationURLCitation(end_index=6520, start_index=6383, title='Frontiers | Unravelling the druggability and immunological roles of the SOCS-family proteins', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1449397/full#:~:text=the%20SOCS4,016')
16. AnnotationURLCitation(end_index=6800, start_index=6663, title='Frontiers | Unravelling the druggability and immunological roles of the SOCS-family proteins', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1449397/full#:~:text=the%20SOCS4,016')
17. AnnotationURLCitation(end_index=7656, start_index=7488, title='Frontiers | Unravelling the druggability and immunological roles of the SOCS-family proteins', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1449397/full#:~:text=SOCS5%20expression%20is%20constitutive%20in,99')
18. AnnotationURLCitation(end_index=7790, start_index=7657, title='SOCS5 suppressor of cytokine signaling 5 [Homo sapiens (human)] - Gene - NCBI', type='url_citation', url='https://www.ncbi.nlm.nih.gov/gene/9655#:~:text=protein%20have%20been%20reported.%20,Try%20the%20new%20%2015')
19. AnnotationURLCitation(end_index=8097, start_index=7929, title='Frontiers | Unravelling the druggability and immunological roles of the SOCS-family proteins', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1449397/full#:~:text=SOCS5%20expression%20is%20constitutive%20in,99')
20. AnnotationURLCitation(end_index=8278, start_index=8162, title='Suppressor of Cytokine Signalling 5 (SOCS5) Modulates Inflammatory Responses during Alphavirus Infection - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9692489/#:~:text=disease%20virus%20,17%20%2C%2025')
21. AnnotationURLCitation(end_index=8991, start_index=8835, title='SOCS5 protein expression summary - The Human Protein Atlas', type='url_citation', url='https://www.proteinatlas.org/ENSG00000171150-SOCS5#:~:text=Subcellular%20location,i%7D%20Intracellular%20TISSUE%20RNA%20EXPRESSION')
22. AnnotationURLCitation(end_index=9322, start_index=9166, title='SOCS5 protein expression summary - The Human Protein Atlas', type='url_citation', url='https://www.proteinatlas.org/ENSG00000171150-SOCS5#:~:text=Subcellular%20location,i%7D%20Intracellular%20TISSUE%20RNA%20EXPRESSION')
23. AnnotationURLCitation(end_index=9591, start_index=9435, title='SOCS5 protein expression summary - The Human Protein Atlas', type='url_citation', url='https://www.proteinatlas.org/ENSG00000171150-SOCS5#:~:text=Subcellular%20location,i%7D%20Intracellular%20TISSUE%20RNA%20EXPRESSION')
24. AnnotationURLCitation(end_index=9942, start_index=9738, title='Frontiers | Unravelling the druggability and immunological roles of the SOCS-family proteins', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1449397/full#:~:text=Structurally%2C%20SOCS7%20is%20very%20alike,similar%20to%20its%20previous%20family')
25. AnnotationURLCitation(end_index=10596, start_index=10435, title='Suppressor of cytokine signaling (SOCS)5 ameliorates influenza infection via inhibition of EGFR signaling - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5354519/#:~:text=The%20experiments%20show%20that%20mice,that%20SOCS5%20levels%20increased%20in')
26. AnnotationURLCitation(end_index=10751, start_index=10597, title='Suppressor of cytokine signaling (SOCS)5 ameliorates influenza infection via inhibition of EGFR signaling - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5354519/#:~:text=were%20lysed%20at%20day%201,figure%20supplement%20is%20available%20for')
27. AnnotationURLCitation(end_index=11767, start_index=11616, title='Frontiers | Unravelling the druggability and immunological roles of the SOCS-family proteins', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1449397/full#:~:text=basophils%20release%20IL,STAT')
28. AnnotationURLCitation(end_index=12246, start_index=12112, title='Frontiers | Unravelling the druggability and immunological roles of the SOCS-family proteins', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1449397/full#:~:text=99,202477099')
29. AnnotationURLCitation(end_index=12870, start_index=12709, title='Frontiers | Unravelling the druggability and immunological roles of the SOCS-family proteins', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1449397/full#:~:text=Th2%20cell%20development%20and%20the,34')
30. AnnotationURLCitation(end_index=13280, start_index=13119, title='Frontiers | Unravelling the druggability and immunological roles of the SOCS-family proteins', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1449397/full#:~:text=Th2%20cell%20development%20and%20the,34')
31. AnnotationURLCitation(end_index=13436, start_index=13281, title='Frontiers | Unravelling the druggability and immunological roles of the SOCS-family proteins', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1449397/full#:~:text=of%20action%20is%20not%20fully,27')
32. AnnotationURLCitation(end_index=13998, start_index=13790, title='Frontiers | Unravelling the druggability and immunological roles of the SOCS-family proteins', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1449397/full#:~:text=The%20wider%20immune%20system%20implications,Th2%20balance%20through%20mediating%20the')
33. AnnotationURLCitation(end_index=14342, start_index=14168, title='Frontiers | Unravelling the druggability and immunological roles of the SOCS-family proteins', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1449397/full#:~:text=The%20wider%20immune%20system%20implications,protein')
34. AnnotationURLCitation(end_index=14749, start_index=14541, title='Frontiers | Unravelling the druggability and immunological roles of the SOCS-family proteins', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1449397/full#:~:text=The%20wider%20immune%20system%20implications,Th2%20balance%20through%20mediating%20the')
35. AnnotationURLCitation(end_index=15038, start_index=14857, title='Frontiers | Unravelling the druggability and immunological roles of the SOCS-family proteins', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1449397/full#:~:text=The%20Th1%20response%20produces%20proinflammatories,protein')
36. AnnotationURLCitation(end_index=15666, start_index=15485, title='Frontiers | Unravelling the druggability and immunological roles of the SOCS-family proteins', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1449397/full#:~:text=The%20Th1%20response%20produces%20proinflammatories,protein')
37. AnnotationURLCitation(end_index=16231, start_index=16078, title='Frontiers | Unravelling the druggability and immunological roles of the SOCS-family proteins', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1449397/full#:~:text=susceptibility%20to%20infection')
38. AnnotationURLCitation(end_index=16378, start_index=16232, title='Frontiers | Unravelling the druggability and immunological roles of the SOCS-family proteins', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1449397/full#:~:text=Brender%20et%C2%A0al,102')
39. AnnotationURLCitation(end_index=16693, start_index=16525, title='Frontiers | Unravelling the druggability and immunological roles of the SOCS-family proteins', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1449397/full#:~:text=SOCS5%20expression%20is%20constitutive%20in,99')
40. AnnotationURLCitation(end_index=16865, start_index=16694, title='Frontiers | Unravelling the druggability and immunological roles of the SOCS-family proteins', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1449397/full#:~:text=reversed%20when%20a%20large%20excess,alpha%2Fbeta')
41. AnnotationURLCitation(end_index=17233, start_index=17062, title='Frontiers | Unravelling the druggability and immunological roles of the SOCS-family proteins', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1449397/full#:~:text=reversed%20when%20a%20large%20excess,alpha%2Fbeta')
42. AnnotationURLCitation(end_index=17599, start_index=17418, title='Frontiers | Unravelling the druggability and immunological roles of the SOCS-family proteins', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1449397/full#:~:text=The%20Th1%20response%20produces%20proinflammatories,protein')
43. AnnotationURLCitation(end_index=18868, start_index=18662, title='Frontiers | Unravelling the druggability and immunological roles of the SOCS-family proteins', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1449397/full#:~:text=interactions%20are%20highlighted%20in%20the,in%20the%20SOCS5%20interaction%20network')
44. AnnotationURLCitation(end_index=19304, start_index=19098, title='Frontiers | Unravelling the druggability and immunological roles of the SOCS-family proteins', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1449397/full#:~:text=interactions%20are%20highlighted%20in%20the,in%20the%20SOCS5%20interaction%20network')
45. AnnotationURLCitation(end_index=20126, start_index=19930, title='Frontiers | Unravelling the druggability and immunological roles of the SOCS-family proteins', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1449397/full#:~:text=play%20a%20role%20in%20regulating,in%20the%20SOCS5%20interaction%20network')
46. AnnotationURLCitation(end_index=20574, start_index=20486, title='Suppressor of Cytokine Signalling 5 (SOCS5) Modulates Inflammatory Responses during Alphavirus Infection - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9692489/#:~:text=,doi')
47. AnnotationURLCitation(end_index=21267, start_index=21064, title='Frontiers | Unravelling the druggability and immunological roles of the SOCS-family proteins', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1449397/full#:~:text=Abnormal%20regulation%20of%20EGF%20signalling,rapid%20infection%20with%20a%20H1N1')
48. AnnotationURLCitation(end_index=21628, start_index=21425, title='Frontiers | Unravelling the druggability and immunological roles of the SOCS-family proteins', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1449397/full#:~:text=Abnormal%20regulation%20of%20EGF%20signalling,rapid%20infection%20with%20a%20H1N1')
49. AnnotationURLCitation(end_index=22061, start_index=21852, title='Frontiers | Unravelling the druggability and immunological roles of the SOCS-family proteins', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1449397/full#:~:text=turn%20activates%20multiple%20STAT%20proteins,to%20affect%20this%20signalling%20cascade')
50. AnnotationURLCitation(end_index=22265, start_index=22062, title='Frontiers | Unravelling the druggability and immunological roles of the SOCS-family proteins', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1449397/full#:~:text=Abnormal%20regulation%20of%20EGF%20signalling,rapid%20infection%20with%20a%20H1N1')
51. AnnotationURLCitation(end_index=22700, start_index=22563, title='Frontiers | Unravelling the druggability and immunological roles of the SOCS-family proteins', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1449397/full#:~:text=the%20SOCS4,016')
52. AnnotationURLCitation(end_index=23101, start_index=22917, title='Frontiers | Unravelling the druggability and immunological roles of the SOCS-family proteins', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1449397/full#:~:text=EGFR%20is%20known%20to%20be,in%20the%20expression%20of%20SOCS4')
53. AnnotationURLCitation(end_index=23630, start_index=23427, title='Frontiers | Unravelling the druggability and immunological roles of the SOCS-family proteins', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1449397/full#:~:text=Abnormal%20regulation%20of%20EGF%20signalling,rapid%20infection%20with%20a%20H1N1')
54. AnnotationURLCitation(end_index=24138, start_index=23929, title='Frontiers | Unravelling the druggability and immunological roles of the SOCS-family proteins', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1449397/full#:~:text=turn%20activates%20multiple%20STAT%20proteins,to%20affect%20this%20signalling%20cascade')
55. AnnotationURLCitation(end_index=24342, start_index=24139, title='Frontiers | Unravelling the druggability and immunological roles of the SOCS-family proteins', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1449397/full#:~:text=Abnormal%20regulation%20of%20EGF%20signalling,rapid%20infection%20with%20a%20H1N1')
56. AnnotationURLCitation(end_index=24903, start_index=24745, title='Suppressor of cytokine signaling (SOCS)5 ameliorates influenza infection via inhibition of EGFR signaling - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5354519/#:~:text=Here%20we%20show%20for%20the,infection%20by%20inhibiting%20EGFR%20activity')
57. AnnotationURLCitation(end_index=25203, start_index=25045, title='Suppressor of cytokine signaling (SOCS)5 ameliorates influenza infection via inhibition of EGFR signaling - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5354519/#:~:text=Here%20we%20show%20for%20the,infection%20by%20inhibiting%20EGFR%20activity')
58. AnnotationURLCitation(end_index=25655, start_index=25497, title='Suppressor of cytokine signaling (SOCS)5 ameliorates influenza infection via inhibition of EGFR signaling - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5354519/#:~:text=Here%20we%20show%20for%20the,infection%20by%20inhibiting%20EGFR%20activity')
59. AnnotationURLCitation(end_index=25934, start_index=25773, title='Suppressor of cytokine signaling (SOCS)5 ameliorates influenza infection via inhibition of EGFR signaling - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5354519/#:~:text=The%20experiments%20show%20that%20mice,that%20SOCS5%20levels%20increased%20in')
60. AnnotationURLCitation(end_index=26083, start_index=25935, title='Frontiers | Unravelling the druggability and immunological roles of the SOCS-family proteins', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1449397/full#:~:text=SOCS5%5E%7B,COPD%29%20have')
61. AnnotationURLCitation(end_index=26456, start_index=26298, title='Suppressor of cytokine signaling (SOCS)5 ameliorates influenza infection via inhibition of EGFR signaling - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5354519/#:~:text=Here%20we%20show%20for%20the,infection%20by%20inhibiting%20EGFR%20activity')
62. AnnotationURLCitation(end_index=26977, start_index=26793, title='Frontiers | Unravelling the druggability and immunological roles of the SOCS-family proteins', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1449397/full#:~:text=EGFR%20is%20known%20to%20be,in%20the%20expression%20of%20SOCS4')
63. AnnotationURLCitation(end_index=27487, start_index=27399, title='Suppressor of Cytokine Signalling 5 (SOCS5) Modulates Inflammatory Responses during Alphavirus Infection - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9692489/#:~:text=,doi')
64. AnnotationURLCitation(end_index=29072, start_index=28924, title='Frontiers | Unravelling the druggability and immunological roles of the SOCS-family proteins', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1449397/full#:~:text=SOCS5%5E%7B,COPD%29%20have')
65. AnnotationURLCitation(end_index=29378, start_index=29230, title='Frontiers | Unravelling the druggability and immunological roles of the SOCS-family proteins', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1449397/full#:~:text=SOCS5%5E%7B,COPD%29%20have')
66. AnnotationURLCitation(end_index=29699, start_index=29525, title='Frontiers | Unravelling the druggability and immunological roles of the SOCS-family proteins', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1449397/full#:~:text=to%20infection%20with%20influenza%20A,COPD%29%20have')
67. AnnotationURLCitation(end_index=29981, start_index=29807, title='Frontiers | Unravelling the druggability and immunological roles of the SOCS-family proteins', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1449397/full#:~:text=to%20infection%20with%20influenza%20A,COPD%29%20have')
68. AnnotationURLCitation(end_index=30808, start_index=30645, title='Suppressor of cytokine signaling (SOCS)5 ameliorates influenza infection via inhibition of EGFR signaling - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5354519/#:~:text=match%20at%20L63%20Conversely%2C%20SOCS5,of%20these%20patients%20to%20influenza')
69. AnnotationURLCitation(end_index=30992, start_index=30809, title='Frontiers | Unravelling the druggability and immunological roles of the SOCS-family proteins', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1449397/full#:~:text=to%20infection%20with%20influenza%20A,sought%20to%20elucidate')
70. AnnotationURLCitation(end_index=31372, start_index=31209, title='Suppressor of cytokine signaling (SOCS)5 ameliorates influenza infection via inhibition of EGFR signaling - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5354519/#:~:text=match%20at%20L63%20Conversely%2C%20SOCS5,of%20these%20patients%20to%20influenza')
71. AnnotationURLCitation(end_index=31895, start_index=31730, title='Suppressor of cytokine signaling (SOCS)5 ameliorates influenza infection via inhibition of EGFR signaling - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5354519/#:~:text=Conversely%2C%20SOCS5%20levels%20in%20lung,of%20these%20patients%20to%20influenza')
72. AnnotationURLCitation(end_index=32349, start_index=32212, title='Suppressor of Cytokine Signalling 5 (SOCS5) Modulates Inflammatory Responses during Alphavirus Infection - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9692489/#:~:text=all%20tissues%20including%20the%20brain,Relative%20to')
73. AnnotationURLCitation(end_index=32521, start_index=32350, title='Suppressor of Cytokine Signalling 5 (SOCS5) Modulates Inflammatory Responses during Alphavirus Infection - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9692489/#:~:text=In%20the%20present%20study%2C%20we,increased%20brain%20inflammation%20and%20exacerbated')
74. AnnotationURLCitation(end_index=32821, start_index=32684, title='Suppressor of Cytokine Signalling 5 (SOCS5) Modulates Inflammatory Responses during Alphavirus Infection - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9692489/#:~:text=all%20tissues%20including%20the%20brain,Relative%20to')
75. AnnotationURLCitation(end_index=33425, start_index=33267, title='Suppressor of Cytokine Signalling 5 (SOCS5) Modulates Inflammatory Responses during Alphavirus Infection - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9692489/#:~:text=infectious%20virus%20were%20lower%20in,was%20a%20general%20trend%20towards')
76. AnnotationURLCitation(end_index=33688, start_index=33557, title='Suppressor of Cytokine Signalling 5 (SOCS5) Modulates Inflammatory Responses during Alphavirus Infection - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9692489/#:~:text=wild,that%20mediates%20the%20critical%20balance')
77. AnnotationURLCitation(end_index=33845, start_index=33689, title='Suppressor of Cytokine Signalling 5 (SOCS5) Modulates Inflammatory Responses during Alphavirus Infection - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9692489/#:~:text=lower%20levels%20of%20virus%20RNA,type%20control%20mice%20%28Figure%202C')
78. AnnotationURLCitation(end_index=34199, start_index=34049, title='Suppressor of Cytokine Signalling 5 (SOCS5) Modulates Inflammatory Responses during Alphavirus Infection - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9692489/#:~:text=match%20at%20L34%20wild,that%20mediates%20the%20critical%20balance')
79. AnnotationURLCitation(end_index=34326, start_index=34200, title='Suppressor of Cytokine Signalling 5 (SOCS5) Modulates Inflammatory Responses during Alphavirus Infection - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9692489/#:~:text=chemokines%20were%20higher%20than%20at,762')
80. AnnotationURLCitation(end_index=34778, start_index=34624, title='Suppressor of Cytokine Signalling 5 (SOCS5) Modulates Inflammatory Responses during Alphavirus Infection - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9692489/#:~:text=Forest%20virus%20,increased%20brain%20inflammation%20and%20exacerbated')
81. AnnotationURLCitation(end_index=36130, start_index=35968, title='Suppressor of Cytokine Signalling 5 (SOCS5) Modulates Inflammatory Responses during Alphavirus Infection - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9692489/#:~:text=demonstrated%20that%20SOCS5%20plays%20a,mouse%20neuronal%20cell%20line%2C%20in')
82. AnnotationURLCitation(end_index=36673, start_index=36557, title='Suppressor of Cytokine Signalling 5 (SOCS5) Modulates Inflammatory Responses during Alphavirus Infection - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9692489/#:~:text=disease%20virus%20,17%20%2C%2025')
83. AnnotationURLCitation(end_index=38638, start_index=38427, title='Frontiers | Unravelling the druggability and immunological roles of the SOCS-family proteins', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1449397/full#:~:text=Emerging%20evidence%20suggests%20that%20SOCS5,SOCS%20family%20member%20regulates%20immune')
84. AnnotationURLCitation(end_index=40119, start_index=39908, title='Frontiers | Unravelling the druggability and immunological roles of the SOCS-family proteins', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1449397/full#:~:text=Emerging%20evidence%20suggests%20that%20SOCS5,SOCS%20family%20member%20regulates%20immune')
85. AnnotationURLCitation(end_index=40930, start_index=40767, title='Frontiers | Unravelling the druggability and immunological roles of the SOCS-family proteins', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1449397/full#:~:text=IL,and%20progression%20of%20the%20disease')
86. AnnotationURLCitation(end_index=41276, start_index=41113, title='Frontiers | Unravelling the druggability and immunological roles of the SOCS-family proteins', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1449397/full#:~:text=IL,and%20progression%20of%20the%20disease')
87. AnnotationURLCitation(end_index=41849, start_index=41686, title='Frontiers | Unravelling the druggability and immunological roles of the SOCS-family proteins', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1449397/full#:~:text=IL,and%20progression%20of%20the%20disease')
88. AnnotationURLCitation(end_index=43172, start_index=43032, title='SOCS5-RBMX stimulates SREBP1-mediated lipogenesis to promote metastasis in steatotic HCC with HBV-related cirrhosis - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10907597/#:~:text=revealed%20that%20high%20expression%20of,IP%20and%20GST')
89. AnnotationURLCitation(end_index=43344, start_index=43173, title='SOCS5-RBMX stimulates SREBP1-mediated lipogenesis to promote metastasis in steatotic HCC with HBV-related cirrhosis - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10907597/#:~:text=The%20suppressor%20of%20cytokine%20signaling,can%20promote%20the%20proliferation%20and')
90. AnnotationURLCitation(end_index=43725, start_index=43581, title='SOCS5-RBMX stimulates SREBP1-mediated lipogenesis to promote metastasis in steatotic HCC with HBV-related cirrhosis - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10907597/#:~:text=To%20identify%20the%20key%20genes,related%20cirrhosis%20HCC')
91. AnnotationURLCitation(end_index=43850, start_index=43726, title='SOCS5-RBMX stimulates SREBP1-mediated lipogenesis to promote metastasis in steatotic HCC with HBV-related cirrhosis - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10907597/#:~:text=The%20IHC%20staining%20results%20of,HCC')
92. AnnotationURLCitation(end_index=44274, start_index=44134, title='SOCS5-RBMX stimulates SREBP1-mediated lipogenesis to promote metastasis in steatotic HCC with HBV-related cirrhosis - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10907597/#:~:text=vivo%20and%20in%20vitro%20experiments%2C,IP%20and%20GST')
93. AnnotationURLCitation(end_index=44633, start_index=44493, title='SOCS5-RBMX stimulates SREBP1-mediated lipogenesis to promote metastasis in steatotic HCC with HBV-related cirrhosis - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10907597/#:~:text=revealed%20that%20high%20expression%20of,IP%20and%20GST')
94. AnnotationURLCitation(end_index=44770, start_index=44634, title='SOCS5-RBMX stimulates SREBP1-mediated lipogenesis to promote metastasis in steatotic HCC with HBV-related cirrhosis - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10907597/#:~:text=pulldown%20experiments%2C%20we%20found%20that,These')
95. AnnotationURLCitation(end_index=45070, start_index=44930, title='SOCS5-RBMX stimulates SREBP1-mediated lipogenesis to promote metastasis in steatotic HCC with HBV-related cirrhosis - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10907597/#:~:text=revealed%20that%20high%20expression%20of,IP%20and%20GST')
96. AnnotationURLCitation(end_index=45191, start_index=45071, title='SOCS5-RBMX stimulates SREBP1-mediated lipogenesis to promote metastasis in steatotic HCC with HBV-related cirrhosis - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10907597/#:~:text=,de%20novo%20lipogenesis%20in%20HCC')
97. AnnotationURLCitation(end_index=46362, start_index=46244, title='SOCS5-RBMX stimulates SREBP1-mediated lipogenesis to promote metastasis in steatotic HCC with HBV-related cirrhosis - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10907597/#:~:text=metastasis,Using%20GST%20pulldown')
98. AnnotationURLCitation(end_index=46799, start_index=46603, title='Frontiers | Unravelling the druggability and immunological roles of the SOCS-family proteins', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1449397/full#:~:text=With%20respect%20to%20ligand%20design,revealed%20a%20distinct%20SOCS%20box')
99. AnnotationURLCitation(end_index=47365, start_index=47178, title='Frontiers | Unravelling the druggability and immunological roles of the SOCS-family proteins', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1449397/full#:~:text=conserved%20SOCS%20Box%20domain%20%E2%80%93,Using%20computational')
100. AnnotationURLCitation(end_index=48273, start_index=48138, title='Frontiers | Unravelling the druggability and immunological roles of the SOCS-family proteins', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1449397/full#:~:text=of%20SOCS5,99')
101. AnnotationURLCitation(end_index=48664, start_index=48509, title='Frontiers | Unravelling the druggability and immunological roles of the SOCS-family proteins', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1449397/full#:~:text=of%20action%20is%20not%20fully,27')
102. AnnotationURLCitation(end_index=48818, start_index=48665, title='Frontiers | Unravelling the druggability and immunological roles of the SOCS-family proteins', type='url_citation', url='https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1449397/full#:~:text=susceptibility%20to%20infection')
103. AnnotationURLCitation(end_index=49888, start_index=49730, title='Suppressor of cytokine signaling (SOCS)5 ameliorates influenza infection via inhibition of EGFR signaling - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5354519/#:~:text=match%20at%20L67%20The%20next,SOCS5%20activity%20in%20influenza%20patients')
104. AnnotationURLCitation(end_index=50069, start_index=49951, title='SOCS5-RBMX stimulates SREBP1-mediated lipogenesis to promote metastasis in steatotic HCC with HBV-related cirrhosis - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10907597/#:~:text=metastasis,Using%20GST%20pulldown')